Configurable collimator controlled using linear motors

Information

  • Patent Grant
  • 10653892
  • Patent Number
    10,653,892
  • Date Filed
    Friday, June 29, 2018
    6 years ago
  • Date Issued
    Tuesday, May 19, 2020
    4 years ago
Abstract
An example device for trimming a particle beam includes: structures made of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam; and linear motors that are controllable to configure the structures to define the edge.
Description
TECHNICAL FIELD

This disclosure relates generally to a configurable collimator that is controlled using linear motors.


BACKGROUND

Particle therapy systems use an accelerator to generate a particle beam for treating afflictions, such as tumors. In operation, particles are accelerated in orbits inside a cavity in the presence of a magnetic field, and are removed from the cavity through an extraction channel. A magnetic field regenerator generates a magnetic field bump near the outside of the cavity to distort the pitch and angle of some orbits so that they precess towards, and eventually into, the extraction channel. A beam, comprised of the particles, exits the extraction channel.


A scanning system is down-beam of the extraction channel. In this context, “down-beam” means closer to an irradiation target (here, relative to the extraction channel). The scanning system moves the particle beam across at least part of the irradiation target to expose various parts of the irradiation target to the particle beam. For example, to treat a tumor, the particle beam may be “scanned” over different cross-sectional layers of the tumor.


The particle beam can damage healthy tissue adjacent to the irradiation target. A structure defining an edge may be used to limit exposure of the healthy tissue to the particle beam. For example, the structure, or a portion thereof, may be placed in between the particle beam and the healthy tissue, thereby preventing exposure of the healthy tissue to the particle beam.


SUMMARY

An example device for trimming a particle beam comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors that are controllable to configure the structures to define the edge. Each of the linear motors comprises a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of each linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component. The example device may also include one or more of the following features, either alone or in combination.


The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets. The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge. The one or more processing devices may be at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.


The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are connected to a same assembly as the structures and the linear motors. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.


The structures may comprise leaves and each magnetic field generator may comprise a pair of magnets, with each leaf being between a corresponding pair of magnets. The example device may comprise a first carriage configured to move in a first dimension, with the first carriage holding the structures and the linear motors; and a second carriage configured to move in a second dimension that is different from the first dimension, with the first carriage being coupled to the second carriage. The structures may be movable also in the first dimension relative to, and separate from movement of, the first carriage. The structures may define a first edge, and the device may further comprise: second structures that are configurable to define a second edge that is movable into a path of the particle beam such that a third part of the particle beam on a first side of the second edge is blocked by the second structures and such that a fourth part of the particle beam on a second side of the second edge is not blocked by the second structures; and second linear motors that are controllable to configure the second structures to define the second edge. The device further may further comprise a third carriage that is movable in the first dimension and that is coupled to the second carriage, with the third carriage holding the second structures and the second linear motors. The second structures may be movable also in the first dimension relative to, and separate from movement of, the third carriage. The first carriage and the third carriage may be controllable to trim a single spot of the particle beam, with the single spot corresponding to a cross-sectional area of the particle beam. The first carriage and the third carriage may be controllable to trim an area having a size that covers multiple spots of the particle beam, with a spot corresponding to a cross-sectional area of the particle beam. The first carriage and the third carriage may be configured to move independently.


An example device to trim a particle beam comprises: a first carriage that is movable in a first dimension; second carriages that are coupled to the first carriage and therefore movable in the first dimension along with the first carriage, with each of the second carriages also being movable in a second dimension that is different from the first dimension. A second carriage among the second carriages comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors to configure the structures to define the edge, with each of the linear motors being controllable to drive a corresponding one of the structures linearly in the second dimension towards, or away from, the second carriage. The example device may comprise one of more of the following features, either alone or in combination.


A linear motor among the linear motors may comprise a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of the linear motor may be connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component. The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets.


The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures in the second dimension to define the edge, with the one or more processing devices being shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.


The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are more tolerant than the one or more processing devices to exposure to the neutron radiation impacting the structures and the linear motors during operation of the device. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.


An example particle therapy system comprises: a particle accelerator to output a particle beam, with the particle accelerator generating neutron radiation in an enclosed treatment space during operation; one or more scanning magnets to move the particle beam relative to an irradiation target in a patient; and a device to trim the particle beam, with the device being between the one or more scanning magnets and the patient. The device comprises structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; and linear motors that are controllable to configure the structures by driving the structures linearly to define the edge. One or more processing devices are configured to control operation of the device to trim the particle beam, with the one or more processing devices being located in an area that is exposed to less than a specified amount of the neutron radiation. The example particle therapy system may comprise one or more of the following features, either alone or in combination.


The area may be a room that is external to the enclosed treatment space. The enclosed treatment space may be at least partly shielded to reduce exposure of the room to the neutron radiation. A linear motor among the linear motors may comprise a movable component and a stationary component, with the stationary component comprising a magnetic field generator to generate a first magnetic field, and with the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. The movable component of the linear motor may be connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component to drive the corresponding structure linearly. The magnetic field generator may comprise magnets having like poles that are aligned, with the one or more coils being at least partly between the magnets.


The device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures, with the encoders being within the enclosed treatment space and subjected to the neutron radiation. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors. The structures may comprise leaves and each magnetic field generator may comprise a pair of magnets, with each leaf being between a corresponding pair of magnets.


The particle accelerator may be, or include, a synchrocyclotron. The particle therapy system may comprise a gantry on which at least the synchrocyclotron is mounted, with the gantry being movable relative to the patient to move the synchrocyclotron relative to the patient.


The synchrocyclotron may comprise: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a particle source, with the voltage source being controlled to sweep the RF voltage over a frequency range in a cycle; a coil to receive electrical current having one of multiple values and to generate a magnetic field corresponding to the electrical current, with the magnetic field for causing the particles to move orbitally within the cavity at an energy that corresponds to the electrical current, the magnetic field being at least 4 Tesla; and an extraction channel to receive the particles from the cavity and to output the particles received from the cavity to the scanning system, with the particles that are output from the cavity having an energy that is based on the electrical current. The synchrocyclotron may be configured to enable setting of the electrical current to one of the multiple values, with each of the multiple values corresponding to a different energy at which particles are output from the cavity. The voltage source may be controllable to sweep the RF voltage over a different frequency ranges, with each different frequency range corresponding to each different energy at which the particles are output from the cavity.


The synchrocyclotron may comprise: a particle source for holding ionized plasma, with the particle source being in a cavity and comprising two parts that are separated at an acceleration region; a voltage source to provide a radio frequency (RF) voltage to the cavity to accelerate particles from the ionized plasma at a separation region of the particle source, with the voltage source being controllable to sweep the RF voltage over a frequency range in a cycle; a coil to receive electrical current to generate a magnetic field based on the electrical current, with the magnetic field for causing the particles to move orbitally within the cavity, with the magnetic field in the cavity being a maximum of 4 Tesla or more; at least one magnetic pole piece, with the at least one magnetic pole piece comprising ferromagnetic material that borders the cavity; and an extraction channel to receive the particles from the cavity and to output the particles received towards the one or more scanning magnets.


An example device for trimming a particle beam comprises: structures comprised of material that blocks passage of the particle beam, with the structures being configurable to define an edge that is movable into a path of the particle beam; and linear motors that are controllable to configure the structures to define the edge. The example device may comprise one or more of the following features, either alone or in combination.


The example device may comprise one or more processing devices to control the linear motors to configure the structures. The one or more processing devices may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge. The one or more processing devices may be at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors. The one or more processing devices may be shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.


The example device may comprise encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures. The encoders may comprise electronic devices that are connected to a same assembly as the structures and the linear motors. The encoders may comprise one or more of laser sensors, optic sensors, or diode sensors.


Two or more of the features described in this disclosure, including those described in this summary section, may be combined to form implementations not specifically described herein.


Control of the various systems described herein, or portions thereof, may be implemented via a computer program product that includes instructions that are stored on one or more non-transitory machine-readable storage media, and that are executable on one or more processing devices (e.g., microprocessor(s), application-specific integrated circuit(s), programmed logic such as field programmable gate array(s), or the like). The systems described herein, or portions thereof, may be implemented as an apparatus, method, or electronic system that may include one or more processing devices and computer memory to store executable instructions to implement control of the stated functions.


The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an example configurable collimator leaf that is usable with the example configurable collimators described herein.



FIG. 2 is a top view of configurable collimator leaves positioned relative to a treatment area of an irradiation target.



FIG. 3 is a top view of configurable collimator leaves positioned relative to a treatment area of an irradiation target.



FIG. 4 is a perspective view of an example configurable collimator.



FIG. 5 is a side view of an example configurable collimator.



FIG. 6 is a perspective, view of an example configurable collimator having components portrayed in see-through to show the interiors thereof.



FIG. 7 is a block diagram of an example linear motor and example configurable collimator leaves controlled thereby.



FIG. 8 is a block diagram of an example set of leaves for a carriage that are controllable by the linear motors described herein.



FIG. 9 shows a cut-away, back view of example implementation of part of a configurable collimator.



FIG. 10 is a top view of configurable collimator leaves on carriages mounted on a track that is curved relative to the direction of a particle beam.



FIG. 11 is a perspective view of a configurable collimator positioned relative to a patient during particle therapy treatment.



FIG. 12 is a cut-away view of part of an example particle accelerator that is usable in the particle therapy system described herein.



FIG. 13 is a perspective view of components of an example scanning system.



FIG. 14 is a perspective view of components of an example scanning system.



FIG. 15 is a front view of an example magnet for use in a scanning system of the type shown in FIGS. 13 and 14.



FIG. 16 is a perspective view of an example magnet for use in a scanning system of the type shown in FIGS. 13 and 14.



FIG. 17 is a perspective view of an example energy degrader (range modulator) for use in a scanning system of the type shown in FIGS. 13 and 14.



FIG. 18 is a perspective view of a process for moving a leaf of an energy degrader in the path of a particle beam.



FIGS. 19 and 20 are front and perspective views, respectively, of an example particle therapy system.



FIG. 21 is a perspective view of an example particle therapy system.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION

Described herein are example implementations of a configurable collimator that may be used to control the extent of radiation, such as a proton or ion beam, applied to a patient. In this regard, a configurable collimator includes a structure that is controllable to allow some radiation to pass to a patient and to block some radiation from passing to the patient. Typically, the radiation that passes is directed to an irradiation target to be treated, and the radiation that is blocked would otherwise hit, and potentially damage, healthy tissue. In operation, the configurable collimator is placed in the radiation path between a radiation source and an irradiation target and is controlled to produce an opening of an appropriate size and shape to allow some radiation to pass through the opening to the irradiation target, while a remainder of the structure blocks some radiation from reaching adjacent tissue. The configurable collimator may be used in any appropriate radiation therapy system, and is not limited to use with any particular type of system.


In some implementations, the configurable collimator contains generally flat structures, which are referred to as “plates” or “leaves”, and which are controllable to move into the “beam” or “treatment” area to block passage of some radiation and allow passage of other radiation. In some implementations, there are two sets of leaves that face each other. The sets of leaves are controllable to produce an opening of size and shape that is appropriate for treatment. For example, each set of leaves is configurable to define an edge that is movable into a path of the particle beam so that a first part of the particle beam on a first side of the edge is blocked by the leaves, and so that a second part of the particle beam on a second side of the edge is not blocked by the leaves and is allowed to pass to the treatment area. In some implementations the leaves are connected to, are part of, or include, linear motors—one per leaf—that are controllable to control movement of the leaves towards or away from the treatment area to define the edge.


In some implementations, the linear motors are controllable to configure a set of leaves to define a first edge, and to configure another set of leaves to define a second edge that faces the first edge. As described herein, each of the linear motors may include a movable component and a stationary component. The stationary component includes a magnetic field generator to generate a first magnetic field. An example of a magnetic field generator includes two stationary magnets that are adjacent and spaced apart, and that have their poles aligned. The movable component includes one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component. For example, the movable component may be a coil-carrying plate between the two magnets that make up the stationary component. When current passes through the coil, that current produces a magnetic field that interacts with the magnetic field produced by the two magnets, and that causes the movable component (e.g., the current-carrying plate) to move relative to the two magnets. Because a leaf is attached to the movable component, the leaf moves along with the movable component. The linear motors of different leaves may be controlled to control movement of the leaves, and thus to define the edges of the configurable collimator described above.


As noted, in some implementations, a linear motor includes two magnets that are adjacent and spaced apart and that have their poles aligned, and a coil-carrying plate that is sandwiched between the two magnets and that moves relative to the two magnets. This configuration allows multiple linear motors to be arranged in a row, each in close proximity to the next, as may be required to control leaves of the configurable collimator. For example, in some implementations, the leaves are on the order of millimeters thick (e.g., five millimeters or less). Leaves of this thickness enable relatively high precision edges; however, leaves of this thickness may make implementation using other types of motors impractical in some cases. However, the linear motors described herein enable use of leaves having thicknesses of this magnitude. For example, the two stationary magnets shield the coil-carrying plate that moves between them, thereby controlling movement of the leaves. By shielding the coil-carrying plate from stray magnetic fields, it is possible to control movement of the plates even when multiple coil-carryings and corresponding stationary magnets are close proximity to each other.


In some implementations, a computing system, which may be comprised of one or more processing devices, is programmed to control the linear motors to thereby control positioning of leaves to define an edge. For example, the computing system may be controllable to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the leaves to define the edge. The computing system is at least partly shielded from exposure to environmental neutron radiation impacting leaves and the linear motors during particle therapy. More specifically, application of particle therapy causes stray neutrons to be present in the treatment room (e.g., a proton center). Stray neutrons can have a deleterious effect on electronics and, therefore, it is beneficial to shield those electronics from the neutrons. For example, processing devices, such as microprocessors, microcontrollers, field-programmable gate arrays (FPGAs), applications-specific circuits (ASICs), and so forth can be susceptible to environmental neutron radiation. Accordingly, in some implementations, the computing system is shielded by locating the computing system remotely from the source of the neutron radiation. For example, the computing system may be shielded by locating the computing system remotely from the collimation device, including the linear motors, that are controlled by the computing system. In some examples, the computing system may be located in a different room from where treatment occurs. The room may be appropriately shielded to reduce, or to prevent, the effects of neutron radiation on the computing system.


In some implementations, motion of the linear motors may be tracked using encoders. In some examples, encoders include electronic devices that are connected to a same assembly as the leaves and the linear motors. The encoders may include or more of laser sensors, optic sensors, or diode sensors. The encoders detect movement of the leaves, e.g., by detecting where markings or other indicia on the leaves, or on structures that are connected to and that move with the leaves, are located relative to the encoders. Information about locations of the leaves is fed back to the computing system, and is used by the computing system to confirm the position of the leaves during operation and, in some implementations, to change their position. The encoders may be, or include, simple electronic sensors that are not as sensitive to neutron radiation as the processing devices above and that, therefore, may be located in the treatment room.



FIG. 1 shows an example of a leaf 140 that may be used in the configurable collimator, although the configurable collimator is not limited to use with this type of leaf. The height 150 of the leaf is along the beam line (e.g., the direction of the particle beam). The length 152 of the leaf is along its direction of actuation into and out of the treatment area, and is based on the field size, or portion thereof, that the system can treat. The field size corresponds to the treatment area that the beam can impact. The width 153 of the leaf is the direction along which multiple leaves stack when actuated. Generally, the more leaves that are used, the higher the resolution of the aperture that can be produced, including for curved boundaries.


In FIG. 1, leaf 140 includes a tongue and groove feature 155 along its side, which is configured to reduce inter-leaf leakage when multiple such leaves stack. In this example, the curved end 156 of leaf 140 is configured to maintain a surface tangent to the beam at all locations in the treatment area. However, as also described herein, the end of each leaf may be flat, not curved.


In some implementations, the configurable collimator leaves have a height that is sufficient to block at least the maximum beam energy (e.g., the maximum energy of the particle beam output by the system). In some implementations, the configurable collimator leaves have a height that blocks less than the maximum beam energy. In some implementations, the configurable collimator leaves have lengths that are dictated not by the area of an entire treatment area, but rather by the area of a single beam spot or multiple beam spots. In this context, a “beam spot” is the cross-sectional area of a particle beam.


In some implementations, the particle therapy system may be configured to treat a tumor having a cross-section that can fit into a 20 cm×20 cm square area. In this example, each leaf in the configurable collimator may have a length of about 2 cm, which is about enough to block particles in half of one beam spot. As noted, the configurable collimator includes sets of leaves that face each other. So, leaves from each set may be controlled to cover the whole, single beam spot, if necessary, thereby preventing passage of radiation. The leaves may also be controllable to create an opening through which some, or all, of the radiation from the single beam spot can pass.


In operation, the configurable collimator is configured to move as the beam scans across the radiation target, and to track the beam's movement during scanning. In this example, the configurable collimator may be configured to move about 20 cm so as to enable coverage over the entirety of the 20 cm×20 cm area. As described above, the configurable collimator may be configured to use enough leaves to cover (or “trim”) one beam spot and, in some case, a small amount of extra area (e.g., 5% extra area, 10% extra area, 15% extra area, or 20% extra area).



FIG. 2 shows an example implementation of a configurable collimator 200. Configurable collimator 200 includes leaves 201 having a height and made of a material, such as nickel, brass, tungsten, or other metal, sufficient to inhibit or prevent passage of radiation at a given energy. For example in some systems, a particle accelerator is configured to generate a particle beam having a maximum energy of 100 MeV to 300 MeV. Accordingly, in such systems, the leaves may be constructed to prevent passage of a beam having an energy of 100 MeV, 150 MeV, 200 MeV, 250 Mev, 300 MeV, and so forth.


Leaves 201 are mounted on carriages to control their movement relative to a treatment area of an irradiation target, such as a cross-sectional layer of a tumor in a patient. The movement is controlled to cause leaves 201 to cover some parts of treatment area 204, thereby preventing radiation from impacting those parts during treatment, while leaving other parts of treatment area exposed to the radiation. In the example implementation of FIG. 2, there are fourteen leaves in total, seven on the left and seven on the right. In some implementations, there may be a different number of leaves, e.g., ten in total, five on the left and five on the right, twelve in total, six on the left and six on the right, and so forth.


The configurable collimator may be used with any appropriate type of radiation therapy system. In an example implementation, the radiation therapy system is a proton therapy system. As described herein, an example proton therapy system scans a proton beam across a treatment area of an irradiation target in order to destroy malignant tissue. During scanning, the particle beam moves across the treatment area to cover the treatment area with radiation. In an example implementation, the particle beam is pulsed. Because the particle beam is pulsed, the affected parts of the treatment area constitute a series of spots, one for each pulse that hits the treatment area. Depending upon the size of the beam, the result may leave some areas untreated. As a result, it may be beneficial to scan the same treatment area more than once in order to ensure that the entire area is treated. Each successive scan may be offset from the other(s) in order to hit all areas. An example of this type of scanning is called pencil-beam scanning, and the repetitive scans are referred to as painting or repainting the treatment area.


The irradiation target is typically three-dimensional in structure. Accordingly, as described herein, the irradiation target is treated cross-sectional layer (or simply “layer”) by layer. That is, a layer of the irradiation target is treated, followed by another treatment of another layer, and so forth until the entire target is treated. Different layers of an irradiation target are treated by varying an energy level of the particle beam. That is, different energy levels of the particle beam impact different layers of the irradiation target, with higher energy levels affecting layers deeper inside the irradiation target relative to the particle beam source. Accordingly, during treatment, the energy level of the particle beam is changed in order to reach, and thus treat, different layers of the irradiation target.



FIG. 2 shows leaves 201 configured allow radiation to impact part of a layer (e.g., the treatment area) and to prevent radiation from impacting other parts of the layer (e.g., healthy tissue). In FIG. 2, locations 202 represent centers of beam spots to be delivered during a scan of a proton beam across treatment area 204. Circle 208 represents a treatment boundary beyond which no radiation is intended to be delivered. Beam spots that are close to this boundary (e.g., within one standard deviation of the particle beam's profile) border healthy tissue. These are spots that are trimmed (that is, blocked) by appropriate configuration and placement of leaves on the configurable collimator. An example of a beam spot to be trimmed is beam spot 211, having its center at location 206. As shown, leaves 201 are configured to block the portion of beam spot 211 that extends beyond circle 208 and into healthy tissue (or at least tissue not designated for treatment).


In an example implementation, on each of two separate carriages, there are five leaves that are about 5 mm in width and two leaves that are about 20 mm in width. In some implementations, on each of two separate carriages, there are seven leaves, two of which each have widths that are three times or more the widths of each of five other leaves. Other implementations may contain different numbers, sizes, and configurations of leaves, and different numbers and configurations of carriages. For example, some implementations may include any number between five and fifty leaves per carriage, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 leaves (or more) per carriage.


The carriages can move both horizontally and vertically, as described herein. The leaves are also movable horizontally relative to each carriage into, and out of, the treatment area. In this way, the leaves are configurable to approximate the shape of the treatment boundary in the region near the area being treated (e.g., circle 211 or a portion thereof in this example).


The leaves may be moved vertically and/or horizontally between different scans of the particle beam so that the leaves are in appropriate positions when the beam is delivered to a particular area. The leaves need not necessarily be moved for every scan pass, but instead may be moved to a location appropriate for an area. In some cases, e.g., for spots interior to the treatment area, radiation treatment may proceed without the trimming provided by the configurable collimator.



FIG. 3 shows another example of leaves 300 that are part of a configurable collimator configured to trim a radiation spot 301 centered at location 302. In this example, there are seven leaves on each of two sides of the configurable collimator (supported by corresponding carriages). The leaves on each side include two leaves that are wider than the other five; however, the configurable collimator is not limited to this configuration. In this case, spot 301 has a radius of 2.5 sigma defining an 8 mm Gaussian radiation spot.



FIGS. 4, 5, and 6 show an example implementation of a configurable collimator, including carriages 413, 414, 415 configured to hold, and to move, the leaves described above both vertically and horizontally relative to the treatment target. As shown, vertical movement includes movement in the Cartesian Z-direction 417, and horizontal movement includes movement in the Cartesian X direction 418 (with the Cartesian Y direction being into, or out of, the page in FIG. 5). FIGS. 5 and 6 show parts of carriage housings as transparent in order to show components inside the housings; however, the housings are not actually transparent.


Carriage 413 is referred to herein as the primary carriage, and carriages 414 and 415 are referred to herein as secondary carriages. Secondary carriages 414, 415 are coupled to primary carriage 413, as shown in FIGS. 4 to 6. In this example, secondary carriages 414, 415 each include a housing that is fixed to primary carriage 415 via a corresponding member 418, 419. In this example, primary carriage 413 is movable vertically relative to the irradiation target and relative to particle accelerator along tracks 420. The vertical movement of primary carriage 413 also causes the secondary carriages to move vertically. In some implementations, the secondary carriages move vertically in concert. In some implementations, vertical movement of each secondary carriage is independent of vertical movement of the other secondary carriage.


As shown in FIGS. 4 to 6, each secondary carriage 414, 415 is connected to a corresponding rod or rail 422, 423, along which the secondary carriage moves. More specifically, in this example, motor 425 drives secondary carriage 414 to move along rod 422 towards or away from secondary carriage 415. Likewise, in this example, motor 426 drives secondary carriage 415 to move along rod 423 towards or away from secondary carriage 414. Control over movement of the primary and secondary carriages is implemented to position the leaves relative to the irradiation target, as described herein. In addition, the leaves themselves are also configured to move in and out of the carriages, as also described herein.


As shown in FIG. 6, a motor 430 drives the vertical movement of primary carriage 413. For example, as shown in FIG. 6, lead screw 431 is coupled to housing 432, which holds motors 425, 426 that drive corresponding secondary carriages 414, 415, and which is mounted on tracks 420. Lead screw 431 is coupled to, and driven vertically by, motor 430. That is, motor 430 drives lead screw 431 vertically, either towards or away from the irradiation target. Because lead screw 431 is fixed to housing 432, this movement also causes housing 432, and thus secondary carriages 414, 415, to move along tracks 420, either towards or away from the irradiation target.


In this example implementation, as noted, seven leaves 435, 436 are mounted on each secondary carriage 414, 415. Each secondary carriage may be configured to move its leaves horizontally into, or out of, the treatment area. The individual leaves on each secondary carriage may be independently and linearly movable, using linear motors, in the X dimension relative to other leaves on the same secondary carriage. In some implementations, the leaves may also be configured to move in the Y dimension. Furthermore, the leaves on one secondary carriage 414 may be movable independently of the leaves on the other secondary carriage 415. These independent movements of leaves on the secondary carriages, together with the vertical movements enabled by the primary carriage, allow the leaves to be moved into various configurations. As a result, the leaves can conform, both horizontally and vertically, to treatment areas that are randomly shaped both in horizontal and vertical dimensions. The sizes and shapes of the leaves may be varied to create different conformations.


The leaves may be made of any appropriate material that prevents or inhibits transmission of radiation. The type of radiation used may dictate what material(s) are used in the leaves. For example, if the radiation is X-ray, the leaves may be made of lead. In the examples described herein, the radiation is a proton or ion beam. Accordingly, different types of metals or other materials may be used for the leaves. For example, the leaves may be made of nickel, tungsten, lead, brass, steel, iron, or any appropriate combinations thereof. The height of each leaf may determine how well that leaf inhibits transmission of radiation.


In some implementations, the leaves may have the same height, whereas in other implementations, some of the leaves may have heights that are different from heights of others of the leaves. For example, in FIGS. 2 to 6, a set of leaves are each 5 mm in height. However, any appropriate heights may be used. For example, leaves 435, 436 may have any of the following (or other heights): 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm, 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, 25 mm, 26 mm, 27 mm, 28 mm, 29 mm, and so forth. The leaves may have any combination of the foregoing heights. In addition, each of the leaves may have a different height than one or more others of the leaves.


In some implementations, shorter leaves (e.g., leaves of lesser height) may be used in connection with longer leaves. In some implementations, the leaves have enough height to completely block the particle beam at the maximum beam energy. In some implementations, the leaves have enough height to block the particle beam at less than the maximum beam energy (and not to block the particle beam at maximum energy). For example, while a proton therapy system may have the capability to deliver a beam of energy 230 MeV that can treat to a depth in the patient of 32 cm, in some implementations, the configurable collimator can only block protons of at most 175 MeV that can treat to a depth of no more than 20 cm. In doing so, less beam-stopping material may be used, e.g., 2.1 cm of Tungsten instead of 3.3 cm, or 3.3 cm of Nickel instead of 5.2 cm. In this example, the proton therapy system would still be capable of treating at depths exceeding 20 cm, but the configurable collimator would not be used for such treatments. This may be deemed acceptable because, in some circumstances, deeper treatments benefit less from the example particle beam collimation that the configurable collimator provides. That is, in some treatment scenarios, shallow, low-energy treatments are where the configurable collimator will be most effective, and there may be engineering advantages to reducing the amount of material in the leaves. Thus, in some example implementations, the configurable collimator may be restricted to use with shallow, lower-than-maximum energy treatments.


In the implementations of FIGS. 2 to 6, the leaves are semi-rectangular in shape and have about the same surface area when viewed from the side. In some implementations, this need not be the case. For example, the leaves may have different shapes than those shown. Example shapes include, but are not limited to, circular shapes, curvilinear shapes, oval shapes, square shapes, and triangular shapes. Furthermore, individual leaves may have different shapes than others of the leaves contained in the same carriage or in a different carriage. For example, one carriage may contain both rectangular and curvilinear shaped leaves.


In some implementations, the leaves have heights that are enough not only to fully stop a particle beam at the maximum expected proton energy (e.g., 3.3 cm of Tungsten at 230 MeV or, e.g., 5.2 cm of nickel), but also to have enough extra material to prevent proton transmission between the leaves. This material may have a tongue and groove structure as shown in FIG. 1, or a similar configuration. The leaf ends may be configured to include curved or tapered surfaces to enhance delivered penumbra for proton beams of various divergence.


In some implementations, there may be more than one primary carriage and corresponding motors and rails. For example, a first primary carriage may control vertical movement of a first secondary carriage, and a second primary carriage may control vertical movement of a second secondary carriage. Therefore, in such implementations, the two secondary carriages can be moved independently in the vertical dimension, if desired. In any case, the primary carriage may be computer controlled. For example, executable instructions are stored in computer memory (e.g., one or more non-transitory machine-readable storage media), and executed by one or more processing devices to control the movement. Control may be performed with, or without, user input during treatment.


As explained, each secondary carriage 414, 415 includes a corresponding motor to control horizontal carriage movement, as described above. In some implementations, all leaves on a single carriage are independently movable using linear motors—with one linear motor controlling each leaf. FIG. 7 shows an example implementation of a linear motors for use in controlling operations of leaves 701, 702, and 703, which may be the type of leaves shown in FIGS. 1 to 6. Although only three leaves are shown in FIG. 6, any appropriate number of leaves may be included, as illustrated by ellipses 706. Furthermore, any appropriate number of linear motors may be configured to control the leaves to move out of a carriage into a treatment area, and from the treatment area back into the carriage.


Taking leaf 702 as an example, an example linear motor that controls operation of leaf 702 includes a movable component and stationary component comprised of two parts—in this example, magnets 710a and 710b. The two magnets are arranged side-by-side, with their poles aligned. That is, as shown, the positive pole (+) of magnet 710a is aligned to the positive pole (+) of magnet 701b, and the negative pole (−) of magnet 701a is aligned to the negative pole (−) of magnet 710b. The movable component comprises a coil-carrying plate 709 between magnets 710a and 710b. Coil-carrying plate 709 is connected, physically, to leaf 702, and controls movement of leaf 702 along the directions of arrow 711, e.g., into and out of a treatment area, to form part of an edge of the configurable collimator.


As explained, coil-carrying plate 709 includes one or more conductive traces or other conductive structures, that pass current in order to generate a magnetic field. The magnetic field is controlled by controlling the current through the coil-carrying plate in order to control movement of the coil carrying plate, and thus of the leaf 702. That is, current through the coils generates a magnetic field that interacts with the magnetic field produced by magnets 710a and 710b. This interaction causes movement of coil carrying plate 709 and of leaf 702 along a direction of arrow 711, either into, or out of, the treatment area. For example, larger magnetic fields generated by the coil-carrying plate 709 may cause the leaf to move into the treatment area, and smaller magnetic fields generated by the coil-carrying plate may cause the leaf to retract away from the treatment area.


In some implementations, the conductive traces or other conductive structures on the coil-carrying plate may include three windings embedded in aluminum. In some implementations, the leaf may be made of nickel, and be physically attached to the coil-carrying plate. In some implementations, the number of windings and the materials used may be different than those described herein. In some implementations, the coil-carrying plate may be an integral part of the leaf. That is, the leaf itself may include the conductive structures or traces.


In some implementations, the linear motors may include a bearing rod for each leaf. In some implementations, the bearing rod may be between the coil-carrying-plate and the leaf to guide movement of the leaf.


As shown in FIG. 7, in some implementations, the current through the coil-carrying plates may be controlled by signals received from a computing system 714. As explained, the computing system may be susceptible to neutron radiation and, therefore, is located in a remote room 716. In some implementations, remote room 716 may be shielded from neutron radiation produced by the particle accelerator. In some implementations, the remote room may be located far enough away from the treatment room 717 so as not to be affected by neutron radiation from the particle accelerator. In some implementations, the computing system may be located in the treatment room, but be shielded from neutron radiation emitted by the particle accelerator. In some implementations, all computing functionality is shielded from neutron radiation, and the electronics that are not shielded can still operate in the presence of neutron radiation. Encoders are examples of such electronics.


In this regard, encoders (not shown) may include or more of laser sensors, optic sensors, or diode sensors. The encoders detect movement of the leaves, e.g., by detecting where markings or other indicia on the leaves or on structures connected to, and that move with, the leaves are located relative to the encoders. This information about where the leaves are is fed back to the computing system, and is used by the computing system to confirm the position of the leaves during operation. The encoders may be located at any appropriate location. In some implementations, the encoders are located on a housing that includes the leaves. As the leaves move, markings or other indicia that move with the leaves move past the encoders. The encoders then relay that information to computing system 714. Computing system 714 may use that information to control operation of the configurable collimator, including positioning the leaves.



FIG. 8 shows an example of components of a carriage 801, which may be of the same type as carriage 414 or 415 of FIG. 4. Carriage 801 includes leaves 802 that are controlled by linear motors of the type described herein. Each leaf 802 may be controlled by a linear motor of the type described in FIG. 7 to create an edge to block at least some radiation from reaching the patient, e.g., to trim one or more spots produced by the particle beam. That is, each linear motor drives its corresponding leaf linearly to reach its position in a configured edge.


Adding rotational degrees of freedom can improve the ability of the configurable collimator to conform to radiation targets. For example, the entirety of the assembly of FIGS. 4 to 6 may be configured to be rotated in a plane perpendicular to the beam direction, in a plane parallel to the beam direction, or in a combination thereof. In some implementations, each individual secondary carriage 414, 415 may be configured to rotate independently in a same plane. In this way, the configurable collimator may provide more flexibility to conform to complex shapes that are not ideally oriented. In some implementations, both the primary carriage and each secondary carriage may be rotatable.


In the example implementations described above, each leaf is independently actuatable using a separate, and independently-controllable, linear motor such that any appropriate shape can be traced with a leaf configuration. It may be, however, that such flexibility is not required to achieve acceptable edge conformality. The leaves could be mechanically constrained with the ability to achieve only a finite number of configurations. For example, the leaves could be restricted to arrangements that put them in a vertical line, forward diagonal shape, backward diagonal shape, concave shape, convex shape, or any other achievable shape. In this way, flexibility could be traded for mechanical simplicity.



FIG. 9 shows a cut-away, back view of example implementation of a configurable collimator containing carriages 901 and 902, which may be of the same type as carriage 414 or 415 of FIG. 4. As shown, carriages 901 and 902 are configured to travel along rail 903, either into, or out of, the treatment area 905. Leaves, such as leaves 907 and 908, are controlled by the linear motors described herein to move into, or out of, treatment area 905 independently of the movement of carriages 901 and 902, respectively, to form edges for trimming the particle beam.


The configurable collimator may be used to collimate edges that are completely internal to the treatment/beam field. If a treatment plan calls for a volume to be treated that completely surrounds a volume to be protected—for example, a tumor that completely surrounds a spinal cord—a single, machined structure will typically be unable to block radiation to the protected volume without blocking some of treated volume as well. The configurable collimator can treat such a field using a sequence of leaf positions. For example, the configurable collimator can be reconfigured dynamically, and during treatment, to protect the areas that require protection, while allowing treatment on areas that require treatment.


In some cases, better beam performance (penumbra or edge sharpness) results when the particle beam is tangent to the surface of a leaf edge. However, since the beam effectively originates from a single point source, the angle with which it passes through the plane of the configurable collimator changes as the beam is moved away from the center of the field. For this reason, leaves may have curved edges, as shown in FIG. 1, so that the edges can always be placed a location that makes them tangent to the particle beam. In an example implementation of the configurable collimator, the tracks on which both primary and secondary carriages move are curved so that flat leaf edges can be used in lieu of curved leaf edges, and so that the flat but remain tangent to the particle beam.



FIG. 10 shows an example implementation of a configurable collimator having curved track 1020, along which carriages move. In the example of FIG. 10, the particle beam 1021 originates from source 1022, which may be a particle accelerator like the synchrocyclotron described herein. Particle beam 1022 may scan through field 1023 and, at one extent, may be at location 1025 and, at another extent, may be at location 1026. Carriages holding leaves 1028 and 1029 are mounted on curved track 1020 so that leaves 1028 and 1028 can move towards or away from each other. In this example, the leaves have straight ends (or “fronts”) 1031, 1031 in contrast to curved end 156 of FIG. 1. By employing a curved track, the particle beam can remain tangent, or substantially tangent, to the straight ends throughout the scan field 1023. Keeping the particle beam tangent to the ends can be advantageous in that it enables the trimming provided by the configurable collimator to be consistent throughout the range of the beam field.


To summarize, in some implementations, the configurable collimator may have a relatively small size, at least in part due to the linear motors described herein. Thus, in contrast to standard multi-leaf collimators, an example configurable collimator may therefore be used to trim a fraction of a treatment area at one time, e.g., an area that is less than the entire treatment area and that is about equal to one spot size, two spot sizes, three spots sizes, four spot sizes, five spot sizes, and so forth. Thus, in some implementations, the configurable collimator may be small enough to trim a single spot at once and may be large enough to trim several spots in one position, but not the entire field without moving. Thus, the configurable collimator may be configured to move around and within the field as the beam scans. That is, in some implementations, the configurable collimator tracks the beam as it scans, and its configuration and reconfiguration may be synchronized to the scanning and to the pulses provided by the beam (e.g., different reconfigurations for different beam pulses and/or locations). By not using leaves large enough to trim an entire treatment area, the configurable collimator can be made smaller and therefore the configurable collimator can be placed closer to the patient with little or no interference from other devices. In some implementations, no leaf of the configurable collimator even has one dimension that spans an entire maximum treatment area. In some implementations, each individual leaf is movable in two dimensions within the treatment area, and the device is mounted on a gantry (e.g., in the context of a particle therapy system such as that described herein) to be rotated on one or more axes and made extendable towards and away from isocenter.


Furthermore, as described herein, use of linear motors to control the leaves enables further reductions in collimator size. In particular, linear motors having stationary magnets and a movable coil-carrying plate enables the leaves to be stacked relatively close together, which enables individual spot trimming, e.g., trimming in the millimeter range. Heretofore, in known linear motors, current-carrying plates were stationary. However, in some cases, that configuration may not be amenable to stacking leaves of the sizes described herein at least because magnetic fields from the stationary current-carrying plates affect adjacent linear motors, thereby leading to less accurate operation or more system complexity to address these adjacent fields. In any case, the known configurations were not conducive to stacking and controlling leaves of the sizes used in the configurable collimator described herein.


A scanning system includes the configurable collimator describe herein, which is placeable relative to the irradiation target to limit the extent of the particle beam and thereby limit the extent of the particle beam. For example, the configurable collimator may be placed in the beam path down-beam of the energy degrader and before the particle beam hits the treatment area of the irradiation target. The configurable collimator is controllable to allow the particle beam to pass therethrough and then hit certain parts of the treatment area, while preventing the particle beam from hitting other parts of the patient. As noted, the configurable collimator may be controlled to prevent the particle beam from hitting healthy tissue or to prevent the particle beam from hitting other parts of the irradiation target (e.g., if certain parts of the target are to receive more radiation than other parts). FIG. 11 depicts placement of an implementation of the configurable collimator 1170 relative to a patient 1171. The direction of beam 1171a is also shown.


As noted, the configurable collimator may be part of, or used with, a scanning system in a particle therapy system. FIG. 12 shows a cross-section of components 1210 of an example superconducting synchrocyclotron that may be used to provide a particle (e.g., proton) beam in the particle therapy system. In this example, components 1210 include a superconducting magnet 1211. The superconducting magnet includes superconducting coils 1212 and 1213. The superconducting coils are formed, e.g., of multiple superconducting strands (e.g., four strands or six strands) wound around a center strand which may itself be superconducting or non-superconducting (e.g., copper). Each of the superconducting coils 1212, 1213 is for conducting a current that generates a magnetic field (B). The resulting magnetic field is shaped by magnetic yokes 1214, 1215. In an example, a cryostat (not shown) uses liquid helium (He) to maintain each coil at superconducting temperatures, e.g., around 4° Kelvin (K). The magnetic yokes 1214, 1215 (or smaller magnetic pole pieces) are located inside the cryostat, and define the shape of a cavity 1216 in which particles are accelerated.


In some implementations, the particle accelerator includes a particle source 1217 (e.g., a Penning Ion Gauge—PIG source) to provide an ionized plasma column to the cavity 1216. Hydrogen gas, or a combination of hydrogen gas and a noble gas, is ionized to produce the plasma column. A voltage source provides a varying radio frequency (RF) voltage to cavity 16 to accelerate pulses of particles from the plasma column within the cavity. The magnetic field in the cavity is shaped to cause particles to move orbitally within the cavity. In some implementations, the maximum magnetic field produced by the superconducting coils may be within the range of 4 Tesla (T) to 20T, as explained herein. The example synchrocyclotron employs a magnetic field that is uniform in rotation angle and falls off in strength with increasing radius. In some implementations, such a field shape can be achieved regardless of the magnitude of the magnetic field.


As noted, in an example, the particle accelerator is a synchrocyclotron. Accordingly, the RF voltage is swept across a range of frequencies to account for relativistic effects on the particles (e.g., increasing particle mass) when accelerating particles within the acceleration cavity. The magnetic field produced by running current through the superconducting coils, together with the shape of the cavity, causes particles accelerated from the plasma column to accelerate orbitally within the cavity and to increase in energy with an increasing number of turns.


As noted, the superconducting coils (called the main coils) can produce relatively high magnetic fields. In an example implementation, the maximum magnetic field generated by a main coil (e.g., at the center of the acceleration cavity) may be within a range of 4T to 20T or more. For example, the superconducting coils may be used in generating magnetic fields at, or that exceed, one or more of the following magnitudes: 4.0T, 4.1T, 4.2T, 4.3T, 4.4T, 4.5T, 4.6T, 4.7T, 4.8T, 4.9T, 5.0T, 5.1T, 5.2T, 5.3T, 5.4T, 5.5T, 5.6T, 5.7T, 5.8T, 5.9T, 6.0T, 6.1T, 6.2T, 6.3T, 6.4T, 6.5T, 6.6T, 6.7T, 6.8T, 6.9T, 7.0T, 7.1T, 7.2T, 7.3T, 7.4T, 7.5T, 7.6T, 7.7T, 7.8T, 7.9T, 8.0T, 8.1T, 8.2T, 8.3T, 8.4T, 8.5T, 8.6T, 8.7T, 8.8T, 8.9T, 9.0T, 9.1T, 9.2T, 9.3T, 9.4T, 9.5T, 9.6T, 9.7T, 9.8T, 9.9T, 10.0T, 10.1T, 10.2T, 10.3T, 10.4T, 10.5T, 10.6T, 10.7T, 10.8T, 10.9T, 11.0T, 11.1T, 11.2T, 11.3T, 11.4T, 11.5T, 11.6T, 11.7T, 11.8T, 11.9T, 12.0T, 12.1T, 12.2T, 12.3T, 12.4T, 12.5T, 12.6T, 12.7T, 12.8T, 12.9T, 13.0T, 13.1T, 13.2T, 13.3T, 13.4T, 13.5T, 13.6T, 13.7T, 13.8T, 13.9T, 14.0T, 14.1T, 14.2T, 14.3T, 14.4T, 14.5T, 14.6T, 14.7T, 14.8T, 14.9T, 15.0T, 15.1T, 15.2T, 15.3T, 15.4T, 15.5T, 15.6T, 15.7T, 15.8T, 15.9T, 16.0T, 16.1T, 16.2T, 16.3T, 16.4T, 16.5T, 16.6T, 16.7T, 16.8T, 16.9T, 17.0T, 17.1T, 17.2T, 17.3T, 17.4T, 17.5T, 17.6T, 17.7T, 17.8T, 17.9T, 18.0T, 18.1T, 18.2T, 18.3T, 18.4T, 18.5T, 18.6T, 18.7T, 18.8T, 18.9T, 19.0T, 19.1T, 19.2T, 19.3T, 19.4T, 19.5T, 19.6T, 19.7T, 19.8T, 19.9T, 20.0T, 20.1T, 20.2T, 20.3T, 20.4T, 20.5T, 20.6T, 20.7T, 20.8T, 20.9T, or more. Furthermore, the superconducting coils may be used in generating magnetic fields that are outside the range of 4T to 20T or that are within the range of 4T to 20T but that are not specifically listed herein.


In some implementations, such as the implementations shown in FIG. 12, the relatively large ferromagnetic magnetic yokes 1214, 1215 act as returns for stray magnetic fields produced by the superconducting coils. In some systems, a magnetic shield (not shown) surrounds the yokes. The return yokes and the shield together act to reduce stray magnetic fields, thereby reducing the possibility that stray magnetic fields will adversely affect the operation of the particle accelerator.


In some implementations, the return yokes and shield may be replaced by, or augmented by, an active return system. An example active return system includes one or more active return coils that conduct current in a direction opposite to current through the main superconducting coils. In some example implementations, there is an active return coil for each superconducting main coil, e.g., two active return coils—one for each main superconducting coil. Each active return coil may also be a superconducting coil that surrounds the outside of a corresponding main superconducting coil concentrically.


By using an active return system, the relatively large ferromagnetic magnetic yokes 1214, 1215 can be replaced with magnetic pole pieces that are smaller and lighter. Accordingly, the size and weight of the synchrocyclotron can be reduced further without sacrificing performance. An example of an active return system that may be used is described in U.S. Pat. No. 8,791,656 entitled “Active Return System”, the contents of which are incorporated herein by reference.


At or near the output of the extraction channel of the particle accelerator, there may be one or more beam shaping elements, such as a scanning system and/or a scattering system. Components of these systems may be mounted on, or otherwise attached to, the nozzle for positioning relatively close to the patient during treatment. In some implementations, however, beam spreader(s) may be mounted closer to (e.g., on) the accelerator or the outer gantry itself (e.g., mounted to the outer gantry in the absence of an accelerator mounted there).


Referring to FIG. 13, in an example implementation, at the output of extraction channel 1320 of synchrocyclotron 1321 (which may have the configuration of FIG. 12) are example scanning components 1322 that may be used to scan the particle beam across all or part of an irradiation target. FIG. 14 also shows examples of the components of FIG. 13. These include, but are not limited to, a scanning magnet(s) 1324, an ion chamber 1325, an energy degrader 1326, and a configurable collimator 1328 of the type described herein. Other components that may be down-beam of the extraction channel are not shown in FIG. 13 or 14, including, e.g., one or more scatterers for changing beam spot size.


In an example operation, scanning magnet 1324 is an example beam spreader, and is controllable in two dimensions (e.g., Cartesian XY dimensions) to position the particle beam in those two dimensions, and to move the particle beam across at least a part (e.g., a cross-section) of an irradiation target. Ion chamber 1325 detects the dosage of the beam and feeds-back that information to a control system to adjust beam movement. Energy degrader 1326 is controllable to move material (e.g., one or more individual plates) into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target. In this way, the energy degrader can position the particle beam at a depth-wise layer of an irradiation target, e.g., to the layer. In some implementations, the energy degrader uses wedges or other types of structures instead of, or in addition to, plates. For example, energy degrader 1326 may be controllable to move material (e.g., one or more individual wedges) into, and out of, the path of the particle beam to change the energy of the particle beam and therefore the depth to which the particle beam will penetrate the irradiation target.



FIGS. 15 and 16 show views of an example scanning magnet 1324. In this example implementation, scanning magnet 1324 includes two coils 1341, which control particle beam movement in the X direction, and two coils 1342, which control particle beam movement in the Y direction. Control is achieved, in some implementations, by varying current through one or both sets of coils to thereby vary the magnetic field(s) produced thereby. By varying the magnetic field(s) appropriately, the particle beam can be moved in the X and/or Y direction across the irradiation target.


Referring back to FIG. 13, a current sensor 1327 may be connected to, or be otherwise associated with, scanning magnet 1324. For example, the current sensor may be in communication with, but not connected to, the scanning magnet. In some implementations, the current sensor samples current applied to the magnet, which may include current to the coil(s) for controlling beam scanning in the X direction and/or current to the coil(s) for controlling beam scanning in the Y direction. The current sensor may sample current through the magnet at times that correspond to the occurrence of pulses in the particle beam or at a rate that exceeds the rate that the pulses occur in the particle beam. In the latter case, the samples, which identify the magnet current, are correlated to detection of the pulses by the ion chamber described below. For example, the times at which pulses are detected using the ion chamber may be correlated in time to samples from the current sensor, thereby identifying the current in the magnet coil(s) at the times of the pulses. Using the magnet current, it thus may be possible to determine the location on the irradiation target (e.g., on a depth-wise layer of the irradiation target) where each pulse, and thus dose of particles, was delivered. The location of the depth-wise layer may be determined based on the configuration of the energy degrader (e.g., the number of plates) in the beam path.


During operation, the magnitude(s) (e.g., value(s)) of the magnet current(s)) may be stored for each location at which a dose is delivered, along with the amount (e.g., intensity) of the dose. A computer system, which may be either on the accelerator or remote from the accelerator and which may include memory and one or more processing devices, may correlate the magnet current to coordinates within the radiation target, and those coordinates may be stored along with the amount of the dose. For example, the location may be identified by depth-wise layer number and Cartesian XY coordinates or by Cartesian XYZ coordinates (with the depth-wise layer corresponding to the Z coordinate). In some implementations, both the magnitude of the magnet current and the coordinate locations may be stored along with the dose at each location. The foregoing information may be stored in memory either on, or remote from, the accelerator. This information may be used during scanning to apply multiple doses of the same or of different amounts to the same locations to achieve target cumulative doses, including at areas of overlap between adjacent/sequential beam fields, as described herein.


In some implementations, ion chamber 1325 detects dosage (e.g., one or more individual doses) applied by the particle beam to positions on an irradiation target by detecting the numbers of ion pairs created within a gas caused by incident radiation. The numbers of ion pairs correspond to the dose provided by the particle beam. That information is fed-back to the computer system and stored in memory along with the time that the dose is provided. This information may be correlated to, and stored in association with, the location at which the dose was provided and/or the magnitude of the magnet current at that time, as described above.


Configurable collimator 1328 may be located down-beam of the scanning magnets and down-beam of the energy degrader, as shown in FIGS. 13 and 14. The configurable collimator may trim the particle beam on a spot-by-spot basis during movement of the particle beam during scanning. For example, the configurable collimator may include sets of leaves that face each other, and that are movable into and out of carriages to create an aperture shape. Parts of the particle beam that exceed the aperture shape are blocked, and do not pass to the patient. The parts of the beam that pass to the patient are at least partly collimated, thereby providing a beam with a relatively precise edge. In some implementations, each leaf in a set of leaves (e.g., on a carriage) in the configurable collimator is controllable using a single linear motor to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the multiple leaves and such that a second part of the particle beam on a second side of the edge is not blocked by the multiple leaves. The leaves in each set are individually controllable during scanning to trim an area as small as a single spot, and can also be used to trim larger multi-spot areas.



FIG. 17 shows a range modulator 1360, which is an example implementation of energy degrader 1326. In some implementations, range modulator 1360 may be located down-beam of the scanning magnets between the configurable collimator and the patient. In some implementations, such as that shown in FIG. 17, the range modulator includes a series of plates 1361. The plates may be made of one or more of the following example materials: polycarbonate, carbon, beryllium or other material of low atomic number. Other materials, however, may be used in place of, or in addition to, these example materials.


One or more of the plates is movable into, or out of, the beam path to thereby affect the energy of the particle beam and, thus, the depth of penetration of the particle beam within the irradiation target. Plates are moved physically into, and out of, the path of the particle beam. For example, as shown in FIG. 18, a plate 1370 moves along the direction of arrow 1372 between positions in the path of the particle beam 1373 and outside the path of the particle beam. The plates are computer-controlled. Generally, the number of plates that are moved into the path of the particle beam corresponds to the depth at which scanning of an irradiation target is to take place. Thus, the particle beam can be positioned into the interior of a target by appropriate control of the plates.


Some components of the scanning system, including the configurable collimator, may be mounted on, or coupled to, a nozzle 1981 of the particle therapy system's inner gantry 1980 (see FIG. 19), and may be controlled by a control system, such as one or more computing devices that also controls operation of other components of the particle therapy system. FIG. 21 shows another implementation of a particle therapy system having an inner gantry 2190 with a nozzle 2191 on which some components of the scanning system, including the configurable collimator may be mounted. In both examples, the nozzle is movable along a track of the inner gantry (1980 or 2190) relative to the patient and the particle accelerator, and is extensible towards, and retractable away from, the patient, thereby also extending and retracting the components mounted thereon.


As noted, the particle beam passes from the range modulator, through the configurable collimator, to the patient. Passage through air can cause the beam spot size to increase. The longer that the beam passes through air, the greater this spot size increase may be. Accordingly, in some implementations, it is advantageous to reduce the maximum distance that the beam can pass through the air. As explained above, in some examples, the components mounted on the nozzle closest to the patient (e.g., a collimator and energy degrader) may reduce the amount that the beam passes through the air. However, in some examples, because of their proximity to the patient, those components may be made relatively small. The size of those components is related to the treatable field size. That is, these smaller components may result in a relatively smaller beam field size.



FIGS. 19 and 20 show parts an example of a particle therapy system 1982 containing a particle accelerator mounted on a gantry—in this example, a superconducting synchrocyclotron having a configuration described herein is used. In some implementations, the gantry is steel and has two legs (not shown) mounted for rotation on two respective bearings that lie on opposite sides of a patient. The gantry may include a steel truss, connected to each of its legs, that is long enough to span a treatment area in which the patient lies and that is attached at both ends to the rotating legs of the gantry. The particle accelerator may be supported by the steel truss. An example of a gantry configuration that may be used is described in U.S. Pat. No. 7,728,311 entitled “Charged Particle Radiation Therapy”, the contents of which are incorporated herein by reference.


In the example of FIGS. 19 and 20, the patient is located on a treatment couch 1984. In this example, treatment couch 1984 includes a platform that supports the patient. The platform also may include one or more restraints (not shown) for holding the patient in place and for keeping the patient substantially immobile during movement of the couch and during treatment. The platform may, or may not, be padded and/or have a shape (e.g., an indentation) that corresponds to the shape of part of the patient. The couch may be moved via arm 1985.



FIG. 21 shows an example of the gantry configuration described in U.S. Pat. No. 7,728,311, and includes components of an alternative implementation of a particle therapy system that usable with the configurable collimator described herein. The example particle therapy system of FIG. 21 includes an inner gantry 2190 having a nozzle 2191, a treatment couch 2192, and a particle accelerator 2193 (e.g., a synchrocyclotron of the type described herein) mounted on an outer gantry 2194 for rotation at least part-way around the patient to deliver radiation to target(s) in the patient. Treatment couch 2192 is controllable and configured to rotate and to translate the patient in the manner described herein.


In the example of FIG. 21, particle accelerator is also mounted to outer gantry 2194 also to enable linear movement (e.g., translational movement) of the particle accelerator in the directions of arrow 2195 along arms 2196. As shown in FIG. 21, the particle accelerator 2193 may be connected to a gimbal 2199 for pivoting motion relative to the gantry. This pivoting motion may be used to position the accelerator, and thus the beam, for treatment.


Operation of the example particle therapy systems described herein, and operation of all or some component thereof, can be controlled (as appropriate), at least in part, using one or more computer program products, e.g., one or more computer programs tangibly embodied in one or more non-transitory machine-readable media, for execution by, or to control the operation of, one or more data processing apparatus, e.g., a programmable processor, a computer, multiple computers, and/or programmable logic components.


A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment. A computer program can be deployed to be executed on one computer or on multiple computers at one site or distributed across multiple sites and interconnected by a network.


Actions associated with implementing all or part of the operations of the example particle therapy systems described herein can be performed by one or more programmable processors executing one or more computer programs to perform the functions described herein. All or part of the operations can be implemented using special purpose logic circuitry, e.g., an FPGA (field programmable gate array) and/or an ASIC (application-specific integrated circuit).


Processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor will receive instructions and data from a read-only storage area or a random access storage area or both. Elements of a computer (including a server) include one or more processors for executing instructions and one or more storage area devices for storing instructions and data. Generally, a computer will also include, or be operatively coupled to receive data from, or transfer data to, or both, one or more machine-readable storage media, such as mass PCBs for storing data, e.g., magnetic, magneto-optical disks, or optical disks. Non-transitory machine-readable storage media suitable for embodying computer program instructions and data include all forms of non-volatile storage area, including by way of example, semiconductor storage area devices, e.g., EPROM, EEPROM, and flash storage area devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.


Any “electrical connection” as used herein may imply a direct physical connection or a wired or wireless connection that includes intervening components but that nevertheless allows electrical signals to flow between connected components. Any “connection” involving electrical circuitry that allows signals to flow, unless stated otherwise, is an electrical connection and not necessarily a direct physical connection regardless of whether the word “electrical” is used to modify “connection”.


Any two more of the foregoing implementations may be used in an appropriate combination with an appropriate particle accelerator (e.g., a synchrocyclotron). Likewise, individual features of any two more of the foregoing implementations may be used in an appropriate combination. Elements may be left out of the processes, systems, apparatus, etc., described herein without adversely affecting their operation. Various separate elements may be combined into one or more individual elements to perform the functions described herein.


In some implementations, the synchrocyclotron used in the particle therapy system described herein may be a variable-energy synchrocyclotron. In some implementations, a variable-energy synchrocyclotron is configured to vary the energy of the output particle beam by varying the magnetic field in which the particle beam is accelerated. For example, the current may be set to any one of multiple values to produce a corresponding magnetic field. In an example implementation, one or more sets of superconducting coils receives variable electrical current to produce a variable magnetic field in the cavity. In some examples, one set of coils receives a fixed electrical current, while one or more other sets of coils receives a variable current so that the total current received by the coil sets varies. In some implementations, all sets of coils are superconducting. In some implementations, some sets of coils, such as the set for the fixed electrical current, are superconducting, while other sets of coils, such as the one or more sets for the variable current, are non-superconducting (e.g., copper) coils.


Generally, in a variable-energy synchrocyclotron, the magnitude of the magnetic field is scalable with the magnitude of the electrical current. Adjusting the total electric current of the coils in a predetermined range can generate a magnetic field that varies in a corresponding, predetermined range. In some examples, a continuous adjustment of the electrical current can lead to a continuous variation of the magnetic field and a continuous variation of the output beam energy. Alternatively, when the electrical current applied to the coils is adjusted in a non-continuous, step-wise manner, the magnetic field and the output beam energy also varies accordingly in a non-continuous (step-wise) manner. The scaling of the magnetic field to the current can allow the variation of the beam energy to be carried out relatively precisely, thus reducing the need for an energy degrader. In a variable-energy synchrocyclotron, the voltage source is controllable to sweep RF voltage over a different frequency ranges, with each different frequency range corresponding to each different energy at which the particles are output from the cavity. An example of a variable-energy synchrocyclotron that may be used in the particle therapy system is described in U.S. Patent Publication No. 2014/0371511 entitled “Particle Accelerator That Produces Charged Particles Having Variable Energies”, the contents of which are incorporated herein by reference. Linear motor-driven collimators may be used in a variable-energy synchrocyclotron system of the type described in U.S. Patent Publication No. 2014/037151.


In some implementations, a particle accelerator other than a synchrocyclotron may be used in the particle therapy system described herein. For example, a cyclotron, a synchrotron, a linear accelerator, or the like may be substituted for the synchrocyclotron described herein. Although a rotational gantry has been described (e.g., the outer gantry), the example particle therapy systems described herein are not limited to use with rotational gantries. Rather, a particle accelerator may be mounted, as appropriate, on any type of robotic or other controllable mechanism(s)—characterized herein also as types of gantries—to implement movement of the particle accelerator. For example, the particle accelerator may be mounted on or more robotic arms to implement rotational, pivotal, and/or translational movement of the accelerator relative to the patient. In some implementations, the particle accelerator may be mounted on a track, and movement along the track may be computer-controlled. In this configuration, rotational and/or translational and/or pivotal movement of the accelerator relative to the patient can also be achieved through appropriate computer control.


The example linear motors described may be used in conjunction with any appropriate features and systems described in U.S. Patent Publication No. 2017/0128746 (application Ser. No. 14/937,048) entitled “Adaptive Aperture”, which is incorporated herein by reference.

Claims
  • 1. A device for trimming a particle beam, comprising: structures comprised of material that blocks passage of the particle beam, the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; andlinear motors that are controllable to configure the structures to define the edge, each of the linear motors comprising a movable component and a stationary component, the stationary component comprising a magnetic field generator to generate a first magnetic field, the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component;wherein the movable component of each linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component.
  • 2. The device of claim 1, wherein the magnetic field generator comprises magnets having like poles that are aligned, the one or more coils being at least partly between the magnets.
  • 3. The device of claim 1, further comprising: one or more processing devices to control the linear motors to configure the structures, the one or more processing devices being configured to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge, the one or more processing devices being at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device.
  • 4. The device of claim 3, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors.
  • 5. The device of claim 3, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
  • 6. The device of claim 3, further comprising: encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures.
  • 7. The device of claim 6, wherein the encoders comprise electronic devices that are connected to a same assembly as the structures and the linear motors.
  • 8. The device of claim 7, wherein the encoders comprise one or more of laser sensors, optic sensors, or diode sensors.
  • 9. The device of claim 1, wherein the structures comprise leaves and each magnetic field generator comprises a pair of magnets, each leaf being partly between a corresponding pair of magnets.
  • 10. The device of claim 1, further comprising: a first carriage configured to move in a first dimension, the first carriage holding the structures and the linear motors; anda second carriage configured to move in a second dimension that is different from the first dimension, the first carriage being coupled to the second carriage.
  • 11. The device of claim 10, wherein the structures define a first edge; wherein the device further comprises: second structures that are configurable to define a second edge that is movable into a path of the particle beam such that a third part of the particle beam on a first side of the second edge is blocked by the second structures and such that a fourth part of the particle beam on a second side of the second edge is not blocked by the second structures; andsecond linear motors that are controllable to configure the second structures to define the second edge; andwherein the device further comprises a third carriage that is movable in the first dimension and that is coupled to the second carriage, the third carriage holding the second structures and the second linear motors.
  • 12. The device of claim 11, wherein the structures are movable also in the first dimension relative to, and separate from movement of, the first carriage.
  • 13. The device of claim 12, wherein the second structures are movable also in the first dimension relative to, and separate from movement of, the third carriage.
  • 14. The device of claim 12, wherein the first carriage and the third carriage are controllable to trim a single spot of the particle beam, the single spot corresponding to a cross-sectional area of the particle beam.
  • 15. The device of claim 12, wherein the first carriage and the third carriage are controllable to trim an area having a size that covers multiple spots of the particle beam, a spot corresponding to a cross-sectional area of the particle beam.
  • 16. The device of claim 12, wherein the first carriage and the third carriage are configured to move independently.
  • 17. A device to trim a particle beam, comprising: a first carriage that is movable in a first dimension;second carriages that are coupled to the first carriage and therefore movable in the first dimension along with the first carriage, each of the second carriages also being movable in a second dimension that is different from the first dimension, a second carriage among the second carriages comprising: structures comprised of material that blocks passage of the particle beam, the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; andlinear motors to configure the structures to define the edge, each of the linear motors being controllable to drive a corresponding one of the structures linearly in the second dimension towards, or away from, the path of the particle beam, each of the linear motors comprising a movable component and a stationary component, the stationary component comprising a magnetic field generator to generate a first magnetic field, the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component.
  • 18. The device of claim 17, wherein the movable component of the linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component.
  • 19. The device of claim 18, wherein the magnetic field generator comprises magnets having like poles that are aligned, the one or more coils being at least partly between the magnets.
  • 20. The device of claim 18, further comprising: one or more processing devices to control the linear motors to configure the structures, the one or more processing devices being configured to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures in the second dimension to define the edge, the one or more processing devices being shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device.
  • 21. The device of claim 20, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors.
  • 22. The device of claim 20, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
  • 23. The device of claim 20, further comprising: encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures.
  • 24. The device of claim 23, wherein the encoders comprise electronic devices that are more tolerant than the one or more processing devices to exposure to the neutron radiation impacting the structures and the linear motors during operation of the device.
  • 25. The device of claim 24, wherein the encoders comprise one or more of laser sensors, optic sensors, or diode sensors.
  • 26. A particle therapy system comprising: a particle accelerator to output a particle beam, the particle accelerator generating neutron radiation in an enclosed treatment space during operation;one or more scanning magnets to move the particle beam relative to an irradiation target in a patient; anda device to trim the particle beam, the device being between the one or more scanning magnets and the patient, the device comprising: structures comprised of material that blocks passage of the particle beam, the structures being configurable to define an edge that is movable into a path of the particle beam such that a first part of the particle beam on a first side of the edge is blocked by the structures and such that a second part of the particle beam on a second side of the edge is not blocked by the structures; andlinear motors that are controllable to configure the structures by driving the structures linearly to define the edge, each of the linear motors comprising a movable component and a stationary component, the stationary component comprising a magnetic field generator to generate a first magnetic field, the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component; andone or more processing devices to control operation of the device to trim the particle beam, the one or more processing devices being located in an area that is exposed to less than a specified amount of the neutron radiation.
  • 27. The particle therapy system of claim 26, wherein the area is a room that is external to the enclosed treatment space.
  • 28. The particle therapy system of claim 27, where the enclosed treatment space is at least partly shielded to reduce exposure of the room to the neutron radiation.
  • 29. The particle therapy system of claim 26, wherein the movable component of the linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component to drive the corresponding structure linearly.
  • 30. The device of claim 29, wherein the magnetic field generator comprises magnets having like poles that are aligned, the one or more coils being at least partly between the magnets.
  • 31. The device of claim 30, further comprising: encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures, the encoders being within the enclosed treatment space and subjected to the neutron radiation.
  • 32. The device of claim 31, wherein the encoders comprise one or more of laser sensors, optic sensors, or diode sensors.
  • 33. The device of claim 26, wherein the structures comprise leaves and each magnetic field generator comprises a pair of magnets, each leaf being at least partly between a corresponding pair of magnets.
  • 34. The particle therapy system of claim 26, wherein the particle accelerator is a synchrocyclotron; and wherein the particle therapy system further comprises a gantry on which at least the synchrocyclotron is mounted, the gantry being movable relative to the patient to move the synchrocyclotron relative to the patient.
  • 35. The particle therapy system of claim 34, wherein the synchrocyclotron comprises: a voltage source to provide a radio frequency (RF) voltage to a cavity to accelerate particles from a particle source, the voltage source being controlled to sweep the RF voltage over a frequency range in a cycle;a coil to receive electrical current having one of multiple values and to generate a magnetic field corresponding to the electrical current, the magnetic field for causing the particles to move orbitally within the cavity at an energy that corresponds to the electrical current, the magnetic field being at least 4 Tesla; andan extraction channel to receive the particles from the cavity and to output the particles received from the cavity to a scanning system comprising the one or more scanning magnets, the particles that are output from the cavity having an energy that is based on the electrical current;wherein the synchrocyclotron is configured to enable setting of the electrical current to one of the multiple values, each of the multiple values corresponding to a different energy at which particles are output from the cavity; andwherein the voltage source is controllable to sweep the RF voltage over a different frequency ranges, each different frequency range corresponding to each different energy at which the particles are output from the cavity.
  • 36. The particle therapy system of claim 34, wherein the synchrocyclotron comprises: a particle source for holding ionized plasma, the particle source being in a cavity and comprising two parts that are separated at an acceleration region;a voltage source to provide a radio frequency (RF) voltage to the cavity to accelerate particles from the ionized plasma at a separation region of the particle source, the voltage source being controllable to sweep the RF voltage over a frequency range in a cycle;a coil to receive electrical current to generate a magnetic field based on the electrical current, the magnetic field for causing the particles to move orbitally within the cavity, the magnetic field in the cavity being a maximum of 4 Tesla or more;at least one magnetic pole piece, the at least one magnetic pole piece comprising ferromagnetic material that borders the cavity; andan extraction channel to receive the particles from the cavity and to output the particles received towards the one or more scanning magnets.
  • 37. A device for trimming a particle beam, comprising: structures comprised of material that blocks passage of the particle beam, the structures being configurable to define an edge that is movable into a path of the particle beam; andlinear motors that are controllable to configure the structures to define the edge, each of the linear motors comprising a movable component and a stationary component, the stationary component comprising a magnetic field generator to generate a first magnetic field, the movable component comprising one or more coils to conduct current to produce a second magnetic field that interacts with the first magnetic field to cause the moveable component to move relative to the stationary component;wherein the movable component of each linear motor is connected to, or part of, a corresponding one of the structures such that the corresponding structure moves along with movement with the movable component.
  • 38. The device of claim 37, further comprising: one or more processing devices to control the linear motors to configure the structures, the one or more processing devices being configured to output one or more control signals to control one or more of the linear motors to extend or to retract one or more of the structures to define the edge, the one or more processing devices being at least partly shielded from exposure to environmental neutron radiation impacting the structures and the linear motors during operation of the device.
  • 39. The device of claim 38, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices remotely from the structures and the linear motors.
  • 40. The device of claim 38, wherein the one or more processing devices are shielded from exposure to the environmental neutron radiation by locating the one more processing devices in a different room from the structures and the linear motors.
  • 41. The device of claim 38, further comprising: encoders that are configured to track movement of the structures and to provide information to the one or more processing devices about the movement of the structures.
  • 42. The device of claim 41, wherein the encoders comprise electronic devices that are connected to a same assembly as the structures and the linear motors.
  • 43. The device of claim 42, wherein the encoders comprise one or more of laser sensors, optic sensors, or diode sensors.
CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Application No. 62/527,539, filed Jun. 30, 2017, the disclosure of which is incorporated by reference herein in its entirety.

US Referenced Citations (1146)
Number Name Date Kind
463291 Dodson Nov 1891 A
773508 Leblanc Oct 1904 A
2280606 Roberts Apr 1942 A
2492324 Salisbury Dec 1949 A
2615129 Mcmillan Oct 1952 A
2616042 Ray Oct 1952 A
2659000 Salisbury Nov 1953 A
2701304 Dickinson Feb 1955 A
2789222 Martin et al. Apr 1957 A
2958327 Geissmann Nov 1960 A
3024379 Verster Mar 1962 A
3175131 Burleigh et al. Mar 1965 A
3432721 Naydan et al. Mar 1969 A
3582650 Avery Jun 1971 A
3679899 Dimeff Jul 1972 A
3689847 Verster Sep 1972 A
3757118 Hodge et al. Sep 1973 A
3868522 Bigham et al. Feb 1975 A
3886367 Castle, Jr. May 1975 A
3925676 Bigham et al. Dec 1975 A
3955089 McIntyre et al. May 1976 A
3958327 Marancik et al. May 1976 A
3992625 Schmidt et al. Nov 1976 A
4038622 Purcell Jul 1977 A
4047068 Ress et al. Sep 1977 A
4112306 Nunan Sep 1978 A
4129784 Tschunt et al. Dec 1978 A
4139777 Rautenbach Feb 1979 A
4197510 Szu Apr 1980 A
4220866 Taumann et al. Sep 1980 A
4230129 LeVeen Oct 1980 A
4256966 Heinz Mar 1981 A
4293772 Stieber Oct 1981 A
4336505 Meyer Jun 1982 A
4342060 Gibson Jul 1982 A
4345210 Tran Aug 1982 A
4353033 Karasawa Oct 1982 A
4425506 Brown et al. Jan 1984 A
4490616 Cipollina et al. Dec 1984 A
4507614 Prono et al. Mar 1985 A
4507616 Blosser et al. Mar 1985 A
4589126 Augustsson et al. May 1986 A
4598208 Brunelli et al. Jul 1986 A
4628523 Heflin Dec 1986 A
4633125 Blosser et al. Dec 1986 A
4641057 Blosser et al. Feb 1987 A
4641104 Blosser et al. Feb 1987 A
4651007 Perusek et al. Mar 1987 A
4680565 Jahnke Jul 1987 A
4705955 Mileikowsky Nov 1987 A
4710722 Jahnke Dec 1987 A
4726046 Nunan Feb 1988 A
4734653 Jahnke Mar 1988 A
4736106 Kashy et al. Apr 1988 A
4736173 Basil, Jr. et al. Apr 1988 A
4737727 Yamada et al. Apr 1988 A
4739173 Blosser et al. Apr 1988 A
4745367 Dustmann et al. May 1988 A
4754147 Maughan et al. Jun 1988 A
4763483 Olsen Aug 1988 A
4767930 Stieber et al. Aug 1988 A
4769623 Marsing et al. Sep 1988 A
4771208 Jongen et al. Sep 1988 A
4783634 Yamamoto et al. Nov 1988 A
4808941 Marsing Feb 1989 A
4812658 Koehler Mar 1989 A
4843333 Marsing et al. Jun 1989 A
4845371 Stieber Jul 1989 A
4865284 Gosis et al. Sep 1989 A
4868843 Nunan Sep 1989 A
4868844 Nunan Sep 1989 A
4870287 Cole et al. Sep 1989 A
4880985 Jones Nov 1989 A
4894541 Ono Jan 1990 A
4896206 Denham Jan 1990 A
4902993 Krevet Feb 1990 A
4904949 Wilson Feb 1990 A
4905267 Miller et al. Feb 1990 A
4917344 Prechter et al. Apr 1990 A
4943781 Wilson et al. Jul 1990 A
4945478 Merickel et al. Jul 1990 A
4968915 Wilson et al. Nov 1990 A
4987309 Klasen et al. Jan 1991 A
4992744 Fujita et al. Feb 1991 A
4996496 Kitamura et al. Feb 1991 A
5006759 Krispel Apr 1991 A
5010562 Hernandez et al. Apr 1991 A
5012111 Ueda Apr 1991 A
5017789 Young et al. May 1991 A
5017882 Finlan May 1991 A
5036290 Sonobe et al. Jul 1991 A
5039057 Prechter et al. Aug 1991 A
5039867 Nishihara et al. Aug 1991 A
5046078 Hernandez et al. Sep 1991 A
5072123 Johnsen Dec 1991 A
5111042 Sullivan et al. May 1992 A
5111173 Matsuda et al. May 1992 A
5117194 Nakanishi et al. May 1992 A
5117212 Yamamoto et al. May 1992 A
5117829 Miller et al. Jun 1992 A
5144647 Kikuchi Sep 1992 A
5148032 Hernandez Sep 1992 A
5166531 Huntzinger Nov 1992 A
5189687 Bova et al. Feb 1993 A
5191706 Cosden Mar 1993 A
5240218 Dye Aug 1993 A
5260579 Yasuda et al. Nov 1993 A
5260581 Lesyna et al. Nov 1993 A
5278533 Kawaguchi Jan 1994 A
5285166 Hiramoto et al. Feb 1994 A
5317164 Kurokawa May 1994 A
5336891 Crewe Aug 1994 A
5341104 Anton et al. Aug 1994 A
5349198 Takanaka Sep 1994 A
5365742 Boffito et al. Nov 1994 A
5374913 Pissantezky et al. Dec 1994 A
5382914 Hamm et al. Jan 1995 A
5401973 McKeown et al. Mar 1995 A
5405235 Lebre et al. Apr 1995 A
5434420 McKeown et al. Jul 1995 A
5440133 Moyers et al. Aug 1995 A
5451794 McKeown et al. Sep 1995 A
5461773 Kawaguchi Oct 1995 A
5463291 Carroll et al. Oct 1995 A
5464411 Schulte et al. Nov 1995 A
5492922 Palkowitz Feb 1996 A
5511549 Legg et al. Apr 1996 A
5521469 Laisne May 1996 A
5538942 Koyama et al. Jul 1996 A
5549616 Schulte et al. Aug 1996 A
5561697 Takafuji et al. Oct 1996 A
5585642 Britton et al. Dec 1996 A
5633747 Nikoonahad May 1997 A
5635721 Bardi et al. Jun 1997 A
5668371 Deasy et al. Sep 1997 A
5672878 Yao Sep 1997 A
5691679 Ackermann et al. Nov 1997 A
5726448 Smith et al. Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5730745 Schulte et al. Mar 1998 A
5748703 Cosman May 1998 A
5751781 Brown et al. May 1998 A
5764723 Weinberger et al. Jun 1998 A
5778047 Mansfield et al. Jul 1998 A
5783914 Hiramoto et al. Jul 1998 A
5784431 Kalend et al. Jul 1998 A
5797924 Schulte et al. Aug 1998 A
5811944 Sampayan et al. Sep 1998 A
5818058 Nakanishi et al. Oct 1998 A
5821705 Caporaso et al. Oct 1998 A
5825845 Blair et al. Oct 1998 A
5841237 Alton Nov 1998 A
5846043 Spath Dec 1998 A
5851182 Sahadevan Dec 1998 A
5866912 Slater et al. Feb 1999 A
5874811 Finlan et al. Feb 1999 A
5895926 Britton et al. Apr 1999 A
5920601 Nigg et al. Jul 1999 A
5929458 Nemezawa et al. Jul 1999 A
5963615 Egley et al. Oct 1999 A
5986274 Akiyama et al. Nov 1999 A
5993373 Nonaka et al. Nov 1999 A
6008499 Hiramoto et al. Dec 1999 A
6034377 Pu Mar 2000 A
6057655 Jongen May 2000 A
6061426 Linders et al. May 2000 A
6064807 Arai et al. May 2000 A
6066851 Madono et al. May 2000 A
6080992 Nonaka et al. Jun 2000 A
6087670 Hiramoto et al. Jul 2000 A
6087672 Matsuda et al. Jul 2000 A
6094760 Nonaka et al. Aug 2000 A
6118848 Reiffel Sep 2000 A
6140021 Nakasuji et al. Oct 2000 A
6144875 Schweikard et al. Nov 2000 A
6158708 Egley et al. Dec 2000 A
6207952 Kan et al. Mar 2001 B1
6219403 Nishihara Apr 2001 B1
6222905 Yoda et al. Apr 2001 B1
6241671 Ritter et al. Jun 2001 B1
6246066 Yuehu Jun 2001 B1
6256591 Yoda et al. Jul 2001 B1
6265837 Akiyama et al. Jul 2001 B1
6268610 Pu Jul 2001 B1
6278239 Caporaso et al. Aug 2001 B1
6279579 Riaziat et al. Aug 2001 B1
6307914 Kunieda et al. Oct 2001 B1
6316776 Hiramoto et al. Nov 2001 B1
6366021 Meddaugh et al. Apr 2002 B1
6369585 Yao Apr 2002 B2
6380545 Yan Apr 2002 B1
6407505 Bertsche Jun 2002 B1
6417634 Bergstrom Jul 2002 B1
6433336 Jongen et al. Aug 2002 B1
6433349 Akiyama et al. Aug 2002 B2
6433494 Kulish et al. Aug 2002 B1
6441569 Janzow Aug 2002 B1
6443349 Van Der Burg Sep 2002 B1
6459769 Cosman Oct 2002 B1
6465957 Whitham et al. Oct 2002 B1
6472834 Hiramoto et al. Oct 2002 B2
6476403 Dolinskii et al. Nov 2002 B1
6492922 New Dec 2002 B1
6493424 Whitham Dec 2002 B2
6498444 Hanna et al. Dec 2002 B1
6501981 Schweikard et al. Dec 2002 B1
6519316 Collins Feb 2003 B1
6593696 Ding et al. Jul 2003 B2
6594336 Nishizawa et al. Jul 2003 B2
6600164 Badura et al. Jul 2003 B1
6617598 Matsuda Sep 2003 B1
6621889 Mostafavi Sep 2003 B1
6630675 Ghelmansarai Oct 2003 B2
6639234 Badura et al. Oct 2003 B1
6646383 Bertsche et al. Nov 2003 B2
6670618 Hartmann et al. Dec 2003 B1
6683162 Scheinberg et al. Jan 2004 B2
6683318 Haberer et al. Jan 2004 B1
6683426 Kleeven Jan 2004 B1
6693283 Eickhoff et al. Feb 2004 B2
6710362 Kraft et al. Mar 2004 B2
6713773 Lyons et al. Mar 2004 B1
6713976 Zumoto et al. Mar 2004 B1
6714620 Caflisch et al. Mar 2004 B2
6717162 Jongen Apr 2004 B1
6745072 Badura et al. Jun 2004 B1
6757355 Siochi Jun 2004 B1
6769806 Moyers Aug 2004 B2
6774383 Norimine et al. Aug 2004 B2
6777689 Nelson Aug 2004 B2
6777700 Yanagisawa et al. Aug 2004 B2
6780149 Schulte Aug 2004 B1
6792078 Kato et al. Sep 2004 B2
6799068 Hartmann et al. Sep 2004 B1
6800866 Amemiya et al. Oct 2004 B2
6803591 Muramatsu et al. Oct 2004 B2
6813336 Siochi Nov 2004 B1
6814694 Pedroni Nov 2004 B1
6819743 Kato et al. Nov 2004 B2
6822244 Beloussov et al. Nov 2004 B2
6823045 Kato et al. Nov 2004 B2
6853142 Chistyakov Feb 2005 B2
6853703 Svatos et al. Feb 2005 B2
6864770 Nemoto et al. Mar 2005 B2
6865254 Nafstadius Mar 2005 B2
6873123 Marchand et al. Mar 2005 B2
6878951 Ma Apr 2005 B2
6891177 Kraft et al. May 2005 B1
6891924 Yoda et al. May 2005 B1
6894300 Reimoser et al. May 2005 B2
6897451 Kaercher et al. May 2005 B2
6907105 Otto Jun 2005 B2
6914396 Symons et al. Jul 2005 B1
6931100 Kato et al. Aug 2005 B2
6936832 Norimine et al. Aug 2005 B2
6953943 Yanagisawa et al. Oct 2005 B2
6965116 Wagner et al. Nov 2005 B1
6969194 Nafstadius Nov 2005 B1
6979832 Yanagisawa et al. Dec 2005 B2
6984835 Harada Jan 2006 B2
6992312 Yanagisawa et al. Jan 2006 B2
6993112 Hesse Jan 2006 B2
6998604 Nishizawa et al. Feb 2006 B2
7008105 Amann et al. Mar 2006 B2
7011447 Moyers Mar 2006 B2
7012267 Moriyama et al. Mar 2006 B2
7014361 Ein-Gal Mar 2006 B1
7026636 Yanagisawa et al. Apr 2006 B2
7038403 Mastrangeli et al. May 2006 B2
7041479 Swartz et al. May 2006 B2
7045781 Adamec et al. May 2006 B2
7049613 Yanagisawa et al. May 2006 B2
7053389 Yanagisawa et al. May 2006 B2
7054801 Sakamoto et al. May 2006 B2
7060997 Norimine et al. Jun 2006 B2
7071479 Yanagisawa et al. Jul 2006 B2
7073508 Moyers Jul 2006 B2
7081619 Bashkirov et al. Jul 2006 B2
7084410 Beloussov et al. Aug 2006 B2
7091478 Haberer Aug 2006 B2
7095823 Topolnjak et al. Aug 2006 B2
7102144 Matsuda et al. Sep 2006 B2
7122811 Matsuda et al. Oct 2006 B2
7122966 Norling et al. Oct 2006 B2
7122978 Nakanishi et al. Oct 2006 B2
7135678 Wang et al. Nov 2006 B2
7138771 Bechthold et al. Nov 2006 B2
7154107 Yanagisawa et al. Dec 2006 B2
7154108 Tadokoro et al. Dec 2006 B2
7154991 Earnst et al. Dec 2006 B2
7162005 Bjorkholm Jan 2007 B2
7173264 Moriyama et al. Feb 2007 B2
7173265 Miller et al. Feb 2007 B2
7173385 Caporaso et al. Feb 2007 B2
7186991 Kato et al. Mar 2007 B2
7193227 Hiramoto et al. Mar 2007 B2
7199382 Rigney et al. Apr 2007 B2
7208748 Sliski et al. Apr 2007 B2
7212608 Nagamine et al. May 2007 B2
7212609 Nagamine et al. May 2007 B2
7221733 Takai et al. May 2007 B1
7227161 Matsuda et al. Jun 2007 B2
7247869 Tadokoro et al. Jul 2007 B2
7257191 Sommer Aug 2007 B2
7259529 Tanaka Aug 2007 B2
7262424 Moriyama et al. Aug 2007 B2
7262565 Fujisawa Aug 2007 B2
7268358 Ma et al. Sep 2007 B2
7274018 Adamec et al. Sep 2007 B2
7280633 Cheng et al. Oct 2007 B2
7295649 Johnsen Nov 2007 B2
7297967 Yanagisawa et al. Nov 2007 B2
7301162 Matsuda et al. Nov 2007 B2
7307264 Brusasco et al. Dec 2007 B2
7317192 Ma Jan 2008 B2
7318805 Schweikard et al. Jan 2008 B2
7319231 Moriyama et al. Jan 2008 B2
7319336 Baur et al. Jan 2008 B2
7331713 Moyers Feb 2008 B2
7332880 Ina et al. Feb 2008 B2
7345291 Kats Mar 2008 B2
7345292 Moriyama et al. Mar 2008 B2
7348557 Armit Mar 2008 B2
7348579 Pedroni Mar 2008 B2
7351988 Naumann et al. Apr 2008 B2
7355189 Yanagisawa et al. Apr 2008 B2
7368740 Beloussov et al. May 2008 B2
7372053 Yamashita et al. May 2008 B2
7378672 Harada May 2008 B2
7381979 Yamashita et al. Jun 2008 B2
7386099 Kasper et al. Jun 2008 B1
7397054 Natori et al. Jul 2008 B2
7397901 Johnsen Jul 2008 B1
7398309 Baumann et al. Jul 2008 B2
7402822 Guertin et al. Jul 2008 B2
7402823 Guertin et al. Jul 2008 B2
7402824 Guertin et al. Jul 2008 B2
7402963 Sliski et al. Jul 2008 B2
7405407 Hiramoto et al. Jul 2008 B2
7425717 Matsuda et al. Sep 2008 B2
7432516 Peggs et al. Oct 2008 B2
7439528 Nishiuchi et al. Oct 2008 B2
7446328 Rigney et al. Nov 2008 B2
7446490 Jongen et al. Nov 2008 B2
7449701 Fujimaki et al. Nov 2008 B2
7453076 Welch et al. Nov 2008 B2
7465944 Ueno et al. Dec 2008 B2
7466085 Nutt Dec 2008 B2
7468506 Rogers et al. Dec 2008 B2
7473913 Hermann et al. Jan 2009 B2
7476867 Fritsch et al. Jan 2009 B2
7476883 Nutt Jan 2009 B2
7482606 Groezinger et al. Jan 2009 B2
7492556 Atkins et al. Feb 2009 B2
7507975 Mohr Mar 2009 B2
7525104 Harada Apr 2009 B2
7531818 Brahme May 2009 B2
7541905 Antaya Jun 2009 B2
7547901 Guertin et al. Jun 2009 B2
7554096 Ward et al. Jun 2009 B2
7554097 Ward et al. Jun 2009 B2
7554275 Amaldi Jun 2009 B2
7555103 Johnsen Jun 2009 B2
7557358 Ward et al. Jul 2009 B2
7557359 Ward et al. Jul 2009 B2
7557360 Ward et al. Jul 2009 B2
7557361 Ward et al. Jul 2009 B2
7560698 Rietzel Jul 2009 B2
7560715 Pedroni Jul 2009 B2
7560717 Matsuda et al. Jul 2009 B2
7567694 Lu et al. Jul 2009 B2
7574251 Lu et al. Aug 2009 B2
7576499 Caporaso et al. Aug 2009 B2
7579603 Birgy et al. Aug 2009 B2
7579610 Grozinger et al. Aug 2009 B2
7582866 Furuhashi et al. Sep 2009 B2
7582885 Katagiri et al. Sep 2009 B2
7582886 Trbojevic Sep 2009 B2
7586112 Chiba et al. Sep 2009 B2
7598497 Yamamoto et al. Oct 2009 B2
7609009 Tanaka et al. Oct 2009 B2
7609809 Kapatoes et al. Oct 2009 B2
7609811 Siljamaki et al. Oct 2009 B1
7615942 Sanders et al. Nov 2009 B2
7626347 Sliski et al. Dec 2009 B2
7629598 Harada Dec 2009 B2
7629599 Hashimoto Dec 2009 B2
7639853 Olivera et al. Dec 2009 B2
7639854 Schnarr et al. Dec 2009 B2
7643661 Ruchala et al. Jan 2010 B2
7656258 Antaya et al. Feb 2010 B1
7659521 Pedroni Feb 2010 B2
7659528 Uematsu Feb 2010 B2
7668291 Nord et al. Feb 2010 B2
7672429 Urano et al. Mar 2010 B2
7679049 Rietzel Mar 2010 B2
7679073 Urano et al. Mar 2010 B2
7682078 Rietzel Mar 2010 B2
7692166 Muraki et al. Apr 2010 B2
7692168 Moriyama et al. Apr 2010 B2
7696499 Miller et al. Apr 2010 B2
7696847 Antaya Apr 2010 B2
7701677 Schultz et al. Apr 2010 B2
7709818 Matsuda et al. May 2010 B2
7710051 Caporaso et al. May 2010 B2
7718982 Sliski et al. May 2010 B2
7723036 Racila et al. May 2010 B2
7728311 Gall Jun 2010 B2
7746978 Cheng et al. Jun 2010 B2
7755068 Ma et al. Jul 2010 B2
7755305 Umezawa et al. Jul 2010 B2
7759642 Nir Jul 2010 B2
7763867 Birgy et al. Jul 2010 B2
7763873 Flynn et al. Jul 2010 B2
7767988 Kaiser et al. Aug 2010 B2
7770231 Prater et al. Aug 2010 B2
7772577 Saito et al. Aug 2010 B2
7773723 Nord et al. Aug 2010 B2
7773788 Lu et al. Aug 2010 B2
7778488 Nord et al. Aug 2010 B2
7783010 Clayton Aug 2010 B2
7784124 Long et al. Aug 2010 B2
7784127 Kuro et al. Aug 2010 B2
7786433 Gunzert-Marx et al. Aug 2010 B2
7786451 Ward et al. Aug 2010 B2
7786452 Ward et al. Aug 2010 B2
7789560 Moyers Sep 2010 B2
7791051 Beloussov et al. Sep 2010 B2
7796731 Nord et al. Sep 2010 B2
7801269 Cravens et al. Sep 2010 B2
7801270 Nord et al. Sep 2010 B2
7801988 Baumann et al. Sep 2010 B2
7807982 Nishiuchi et al. Oct 2010 B2
7809107 Nord et al. Oct 2010 B2
7812319 Diehl et al. Oct 2010 B2
7812326 Grozinger et al. Oct 2010 B2
7816657 Hansmann et al. Oct 2010 B2
7817778 Nord et al. Oct 2010 B2
7817836 Chao et al. Oct 2010 B2
7818045 Rietzel Oct 2010 B2
7825388 Nihongi et al. Nov 2010 B2
7826593 Svensson et al. Nov 2010 B2
7834334 Grozinger et al. Nov 2010 B2
7834336 Boeh et al. Nov 2010 B2
7835494 Nord et al. Nov 2010 B2
7835502 Spence et al. Nov 2010 B2
7839972 Ruchala et al. Nov 2010 B2
7839973 Nord et al. Nov 2010 B2
7848488 Mansfield Dec 2010 B2
7857756 Warren et al. Dec 2010 B2
7858592 Shames et al. Dec 2010 B2
7860216 Jongen et al. Dec 2010 B2
7860550 Saracen et al. Dec 2010 B2
7868301 Diehl Jan 2011 B2
7875846 Gunzert-Marx et al. Jan 2011 B2
7875861 Huttenberger et al. Jan 2011 B2
7875868 Moriyama et al. Jan 2011 B2
7881431 Aoi et al. Feb 2011 B2
7894574 Nord et al. Feb 2011 B1
7903781 Foland et al. Mar 2011 B2
7906769 Blasche et al. Mar 2011 B2
7907987 Dempsey Mar 2011 B2
7914734 Livingston Mar 2011 B2
7919765 Timmer Apr 2011 B2
7920040 Antaya et al. Apr 2011 B2
7920675 Lomax et al. Apr 2011 B2
7928415 Bert et al. Apr 2011 B2
7934869 Ivanov et al. May 2011 B2
7939809 Balakin May 2011 B2
7940881 Jongen et al. May 2011 B2
7940894 Balakin May 2011 B2
7943913 Balakin May 2011 B2
7947969 Pu May 2011 B2
7949096 Cheng et al. May 2011 B2
7950587 Henson et al. May 2011 B2
7953205 Balakin May 2011 B2
7957508 Brooks et al. Jun 2011 B2
7960710 Kruip et al. Jun 2011 B2
7961844 Takeda et al. Jun 2011 B2
7977648 Westerly et al. Jul 2011 B2
7977656 Fujimaki et al. Jul 2011 B2
7977657 Flynn et al. Jul 2011 B2
7982198 Nishiuchi et al. Jul 2011 B2
7982416 Tanaka et al. Jul 2011 B2
7984715 Moyers Jul 2011 B2
7986768 Nord et al. Jul 2011 B2
7987053 Schaffner Jul 2011 B2
7989785 Emhofer et al. Aug 2011 B2
7990524 Jureller et al. Aug 2011 B2
7997553 Sloan et al. Aug 2011 B2
8002466 Von Neubeck et al. Aug 2011 B2
8003964 Stark et al. Aug 2011 B2
8009803 Nord et al. Aug 2011 B2
8009804 Siljamaki et al. Aug 2011 B2
8016336 Messinger et al. Sep 2011 B2
8039822 Rietzel Oct 2011 B2
8041006 Boyden et al. Oct 2011 B2
8044364 Yamamoto Oct 2011 B2
8045679 Balakin Oct 2011 B2
8049187 Tachikawa Nov 2011 B2
8053508 Korkut et al. Nov 2011 B2
8053739 Rietzel Nov 2011 B2
8053745 Moore Nov 2011 B2
8053746 Timmer et al. Nov 2011 B2
8063381 Tsoupas et al. Nov 2011 B2
8067748 Balakin Nov 2011 B2
8069675 Radovinsky et al. Dec 2011 B2
8071966 Kaiser et al. Dec 2011 B2
8080801 Safai Dec 2011 B2
8085899 Nord et al. Dec 2011 B2
8089054 Balakin Jan 2012 B2
8090074 Filiberti et al. Jan 2012 B2
8093564 Balakin Jan 2012 B2
8093568 Mackie et al. Jan 2012 B2
8111125 Antaya et al. Feb 2012 B2
8129694 Balakin Mar 2012 B2
8129699 Balakin Mar 2012 B2
8144832 Balakin Mar 2012 B2
8153989 Tachikawa et al. Apr 2012 B2
8154001 Flynn et al. Apr 2012 B2
8163709 Kodym et al. Apr 2012 B2
8173981 Trbojevic May 2012 B2
8178859 Balakin May 2012 B2
8183541 Wilkens et al. May 2012 B2
8188688 Balakin May 2012 B2
8189889 Pearlstein et al. May 2012 B2
8190233 Dempsey May 2012 B2
8198607 Balakin Jun 2012 B2
8207656 Baumgartner et al. Jun 2012 B2
8222613 Tajiri et al. Jul 2012 B2
8227768 Smick et al. Jul 2012 B2
8229072 Balakin Jul 2012 B2
8232536 Harada Jul 2012 B2
8238513 Ma Aug 2012 B2
8253121 Gnutzmann et al. Aug 2012 B2
8254521 Brooks et al. Aug 2012 B2
8263954 Iwata Sep 2012 B2
8283645 Guneysel Oct 2012 B2
8288742 Balakin Oct 2012 B2
8291717 Radovinsky et al. Oct 2012 B2
8294127 Tachibana Oct 2012 B2
8304725 Komuro et al. Nov 2012 B2
8304750 Preikszas et al. Nov 2012 B2
8309941 Balakin Nov 2012 B2
8330132 Guertin et al. Dec 2012 B2
8334520 Otaka et al. Dec 2012 B2
8335397 Takane et al. Dec 2012 B2
8344340 Gall et al. Jan 2013 B2
8350214 Otaki et al. Jan 2013 B2
8351571 Brinks et al. Jan 2013 B2
8354656 Beloussov et al. Jan 2013 B2
8368038 Balakin Feb 2013 B2
8368043 Havelange et al. Feb 2013 B2
8373143 Balakin Feb 2013 B2
8373145 Balakin Feb 2013 B2
8373146 Balakin Feb 2013 B2
8374314 Balakin Feb 2013 B2
8378299 Frosien Feb 2013 B2
8378311 Balakin Feb 2013 B2
8378312 Gordon et al. Feb 2013 B1
8378321 Balakin Feb 2013 B2
8382943 Clark Feb 2013 B2
8384053 Balakin Feb 2013 B2
8389949 Harada et al. Mar 2013 B2
8399866 Balakin Mar 2013 B2
8405042 Honda et al. Mar 2013 B2
8405056 Amaldi et al. Mar 2013 B2
8415643 Balakin Apr 2013 B2
8416918 Nord et al. Apr 2013 B2
8421041 Balakin Apr 2013 B2
8426833 Trbojevic Apr 2013 B2
8436323 Iseki et al. May 2013 B2
8436325 Noda et al. May 2013 B2
8436327 Balakin May 2013 B2
8440987 Stephani et al. May 2013 B2
8445872 Behrens et al. May 2013 B2
8459714 Pomper et al. Jun 2013 B2
8461559 Lomax Jun 2013 B2
8466441 Iwata et al. Jun 2013 B2
8472583 Star-Lack et al. Jun 2013 B2
8481951 Jongen et al. Jul 2013 B2
8483357 Siljamaki et al. Jul 2013 B2
8487278 Balakin Jul 2013 B2
8487282 Iseki et al. Jul 2013 B2
8507195 Richer et al. Aug 2013 B2
8519365 Balakin Aug 2013 B2
8525419 Smith et al. Sep 2013 B2
8525447 Antaya Sep 2013 B2
8525448 Tanaka et al. Sep 2013 B2
8536548 Otani et al. Sep 2013 B2
8541762 Claereboudt et al. Sep 2013 B2
8546769 Uno Oct 2013 B2
8552406 Phaneuf et al. Oct 2013 B2
8552408 Hanawa et al. Oct 2013 B2
8558461 Poehlmann-Martins et al. Oct 2013 B2
8558485 Antaya Oct 2013 B2
8565377 Robar et al. Oct 2013 B2
8569717 Balakin Oct 2013 B2
8575563 Cameron et al. Nov 2013 B2
8575564 Iwata Nov 2013 B2
8575579 Moskvin et al. Nov 2013 B2
8581215 Balakin Nov 2013 B2
8581218 Fujimoto et al. Nov 2013 B2
8581523 Gall et al. Nov 2013 B2
8581525 Antaya et al. Nov 2013 B2
8586948 Pu et al. Nov 2013 B2
8598543 Balakin Dec 2013 B2
8601116 Baumann et al. Dec 2013 B2
8604454 Guertin et al. Dec 2013 B2
8613694 Walsh Dec 2013 B2
8614554 Balakin Dec 2013 B2
8614612 Antaya et al. Dec 2013 B2
8618519 Ueda Dec 2013 B2
8618521 Loo et al. Dec 2013 B2
8619242 Suzuki Dec 2013 B2
8624528 Balakin Jan 2014 B2
8625739 Balakin Jan 2014 B2
8627822 Balakin Jan 2014 B2
8632448 Schulte et al. Jan 2014 B1
8633160 Belmares et al. Jan 2014 B2
8637818 Balakin Jan 2014 B2
8637839 Brauer Jan 2014 B2
8642978 Balakin Feb 2014 B2
8643314 Touchi Feb 2014 B2
8644571 Schulte et al. Feb 2014 B1
8653314 Pelati et al. Feb 2014 B2
8653473 Yajima Feb 2014 B2
8657354 Pomper et al. Feb 2014 B2
8657743 Rietzel et al. Feb 2014 B2
8688197 Balakin Apr 2014 B2
8702578 Fahrig et al. Apr 2014 B2
8710462 Balakin Apr 2014 B2
8712011 Robar et al. Apr 2014 B2
8716663 Brusasco et al. May 2014 B2
8718231 Balakin May 2014 B2
8735848 Asaba May 2014 B2
8748852 Jongen Jun 2014 B2
8750453 Cheng et al. Jun 2014 B2
8754386 Iwata Jun 2014 B2
8766217 Balakin Jul 2014 B2
8766218 Jongen Jul 2014 B2
8771754 Hallahan Jul 2014 B2
8791435 Balakin Jul 2014 B2
8791656 Zwart et al. Jul 2014 B1
8796648 Fujimoto et al. Aug 2014 B2
8822965 Asaba Sep 2014 B2
8835885 Ogasawara Sep 2014 B2
8847179 Fujitaka et al. Sep 2014 B2
8859264 Bert et al. Oct 2014 B2
8866109 Sasai Oct 2014 B2
8890097 Iwata Nov 2014 B2
8896239 Balakin Nov 2014 B2
8897857 Tome et al. Nov 2014 B2
8901509 Balakin Dec 2014 B2
8901520 Tachibana et al. Dec 2014 B2
8907309 Spotts Dec 2014 B2
8907311 Gall et al. Dec 2014 B2
8907594 Begg et al. Dec 2014 B2
8916838 Claereboudt et al. Dec 2014 B2
8916841 Totake et al. Dec 2014 B2
8916843 Gall et al. Dec 2014 B2
8927946 Behrens et al. Jan 2015 B2
8927950 Gall et al. Jan 2015 B2
8933650 O'Neal, III et al. Jan 2015 B2
8941083 Stark et al. Jan 2015 B2
8941084 Balakin Jan 2015 B2
8941086 Yajima Jan 2015 B2
8947021 Tsutsui Feb 2015 B2
8948341 Beckman Feb 2015 B2
8952343 Stephani et al. Feb 2015 B2
8952634 Sliski et al. Feb 2015 B2
8957396 Balakin Feb 2015 B2
8963111 Claereboudt et al. Feb 2015 B2
8963112 Balakin Feb 2015 B1
8964936 Brooks et al. Feb 2015 B2
8969834 Balakin Mar 2015 B2
8970137 Gall et al. Mar 2015 B2
8971363 Levecq et al. Mar 2015 B2
8975600 Balakin Mar 2015 B2
8975602 Huber et al. Mar 2015 B2
8975836 Bromberg et al. Mar 2015 B2
8986186 Zhang et al. Mar 2015 B2
8993522 Vidyasagar et al. Mar 2015 B2
9006693 Sasai Apr 2015 B2
9007740 Touchi Apr 2015 B2
9012832 Bert et al. Apr 2015 B2
9012866 Benna et al. Apr 2015 B2
9012873 Fujimoto et al. Apr 2015 B2
9018601 Balakin Apr 2015 B2
9018603 Loo et al. Apr 2015 B2
9024256 Ruan et al. May 2015 B2
9029760 Beddar et al. May 2015 B2
9044600 Balakin Jun 2015 B2
9056199 Balakin Jun 2015 B2
9058910 Balakin Jun 2015 B2
9060998 Stockfleth Jun 2015 B2
9061142 Vilsmeier Jun 2015 B2
9061143 Sasai et al. Jun 2015 B2
9084887 Schulte et al. Jul 2015 B2
9084890 Iwata Jul 2015 B2
9089696 Verhaegen et al. Jul 2015 B2
9093209 Jongen Jul 2015 B2
9095040 Balakin Jul 2015 B2
9108050 Bula et al. Aug 2015 B2
9114253 Dempsey Aug 2015 B2
9142385 Iwanaga Sep 2015 B1
9155186 Zwart et al. Oct 2015 B2
9155908 Meltsner et al. Oct 2015 B2
9185789 Zwart et al. Nov 2015 B2
9186525 Prieels et al. Nov 2015 B2
9188685 Takayanagi et al. Nov 2015 B2
9196082 Pearlstein et al. Nov 2015 B2
9220920 Schulte et al. Dec 2015 B2
9220923 Yajima et al. Dec 2015 B2
9237640 Abs et al. Jan 2016 B2
9237642 Kleeven Jan 2016 B2
9245336 Mallya et al. Jan 2016 B2
9254396 Mihaylov Feb 2016 B2
9259155 Bharat et al. Feb 2016 B2
9271385 Verbruggen et al. Feb 2016 B2
9283406 Prieels Mar 2016 B2
9283407 Benna et al. Mar 2016 B2
9289140 Ross et al. Mar 2016 B2
9289624 Jongen Mar 2016 B2
9297912 Campbell et al. Mar 2016 B2
9301384 Zwart et al. Mar 2016 B2
9302121 Totake et al. Apr 2016 B2
9305742 Aptaker et al. Apr 2016 B2
9324468 Mansfield et al. Apr 2016 B2
9355784 Abs May 2016 B2
9364688 Pausch et al. Jun 2016 B2
9370089 Ungaro et al. Jun 2016 B2
9381379 Beckman Jul 2016 B2
9393443 Fujimoto et al. Jul 2016 B2
9417302 Kuhn Aug 2016 B2
9451688 Jongen Sep 2016 B2
9451689 Tsutsui Sep 2016 B2
9452300 Anferov Sep 2016 B2
9452301 Gall et al. Sep 2016 B2
9468608 Lin et al. Oct 2016 B2
9492684 Takayanagi et al. Nov 2016 B2
9776017 Flynn et al. Oct 2017 B2
9962560 Zwart et al. May 2018 B2
20010022502 Akiyama et al. Sep 2001 A1
20020058007 Scheinberg et al. May 2002 A1
20020101959 Kato et al. Aug 2002 A1
20020172317 Maksimchuk et al. Nov 2002 A1
20030048080 Amemiya et al. Mar 2003 A1
20030125622 Schweikard et al. Jul 2003 A1
20030136924 Kraft et al. Jul 2003 A1
20030152197 Moyers Aug 2003 A1
20030163015 Yanagisawa et al. Aug 2003 A1
20030183779 Norimine et al. Oct 2003 A1
20030234369 Glukhoy Dec 2003 A1
20040000650 Yanagisawa et al. Jan 2004 A1
20040017888 Seppi et al. Jan 2004 A1
20040056212 Yanagisawa et al. Mar 2004 A1
20040061077 Muramatsu et al. Apr 2004 A1
20040061078 Muramatsu et al. Apr 2004 A1
20040085023 Chistyakov May 2004 A1
20040098445 Baumann et al. May 2004 A1
20040111134 Muramatsu et al. Jun 2004 A1
20040118081 Reimoser et al. Jun 2004 A1
20040149934 Yanagisawa et al. Aug 2004 A1
20040155206 Marchand et al. Aug 2004 A1
20040159795 Kaercher et al. Aug 2004 A1
20040164254 Beloussov et al. Aug 2004 A1
20040173763 Moriyama et al. Sep 2004 A1
20040174958 Moriyama et al. Sep 2004 A1
20040183033 Moriyama et al. Sep 2004 A1
20040183035 Yanagisawa et al. Sep 2004 A1
20040190680 Chang Sep 2004 A1
20040200982 Moriyama et al. Oct 2004 A1
20040200983 Fujimaki et al. Oct 2004 A1
20040213381 Harada Oct 2004 A1
20040227104 Matsuda et al. Nov 2004 A1
20040232356 Norimine et al. Nov 2004 A1
20040240626 Moyers Dec 2004 A1
20050008123 Topolnjak et al. Jan 2005 A1
20050029472 Ueno et al. Feb 2005 A1
20050051740 Yanagisawa et al. Mar 2005 A1
20050058245 Ein-Gal Mar 2005 A1
20050072940 Beloussov et al. Apr 2005 A1
20050079235 Stockfleth Apr 2005 A1
20050087700 Tadokoro et al. Apr 2005 A1
20050089141 Brown Apr 2005 A1
20050099145 Nishiuchi et al. May 2005 A1
20050113327 Roiz et al. May 2005 A1
20050127306 Yanagisawa et al. Jun 2005 A1
20050139787 Chiba et al. Jun 2005 A1
20050161618 Pedroni Jul 2005 A1
20050167616 Yanagisawa et al. Aug 2005 A1
20050184686 Caporaso et al. Aug 2005 A1
20050186179 Harats et al. Aug 2005 A1
20050205806 Tadokoro et al. Sep 2005 A1
20050228255 Saracen et al. Oct 2005 A1
20050231138 Nakanishi et al. Oct 2005 A1
20050234327 Saracen et al. Oct 2005 A1
20050247890 Norimine et al. Nov 2005 A1
20050259779 Abraham-Fuchs et al. Nov 2005 A1
20060017015 Sliski et al. Jan 2006 A1
20060033042 Groezinger et al. Feb 2006 A1
20060067468 Rietzel Mar 2006 A1
20060126792 Li Jun 2006 A1
20060127879 Fuccione Jun 2006 A1
20060145088 Ma Jul 2006 A1
20060175991 Fujisawa Aug 2006 A1
20060192146 Yanagisawa et al. Aug 2006 A1
20060204478 Harats et al. Sep 2006 A1
20060219948 Ueno et al. Oct 2006 A1
20060284562 Hruby et al. Dec 2006 A1
20070001128 Sliski et al. Jan 2007 A1
20070013273 Albert et al. Jan 2007 A1
20070014654 Haverfield et al. Jan 2007 A1
20070018120 Beloussov et al. Jan 2007 A1
20070023699 Yamashita et al. Feb 2007 A1
20070029510 Hermann et al. Feb 2007 A1
20070031337 Schulte Feb 2007 A1
20070034812 Ma et al. Feb 2007 A1
20070051904 Kaiser et al. Mar 2007 A1
20070053484 Chiba et al. Mar 2007 A1
20070059387 Stockfleth Mar 2007 A1
20070075273 Birgy et al. Apr 2007 A1
20070083101 Rietzel Apr 2007 A1
20070092812 Caporaso et al. Apr 2007 A1
20070108922 Amaldi May 2007 A1
20070114464 Birgy et al. May 2007 A1
20070114471 Birgy et al. May 2007 A1
20070114945 Mattaboni et al. May 2007 A1
20070145916 Caporaso et al. Jun 2007 A1
20070171015 Antaya Jul 2007 A1
20070181519 Khoshnevis Aug 2007 A1
20070217575 Kaiser et al. Sep 2007 A1
20070262269 Trbojevic Nov 2007 A1
20070284548 Kaiser et al. Dec 2007 A1
20080023644 Pedroni Jan 2008 A1
20080029706 Kaiser et al. Feb 2008 A1
20080031414 Coppens Feb 2008 A1
20080061241 Rietzel Mar 2008 A1
20080063147 Juschka et al. Mar 2008 A1
20080073591 Mohr Mar 2008 A1
20080078942 Rietzel Apr 2008 A1
20080093567 Gall Apr 2008 A1
20080123816 Mori et al. May 2008 A1
20080131419 Roiz et al. Jun 2008 A1
20080159478 Keall et al. Jul 2008 A1
20080179544 Kaiser et al. Jul 2008 A1
20080191142 Pedroni Aug 2008 A1
20080191152 Grozinger et al. Aug 2008 A1
20080205599 Hashimoto Aug 2008 A1
20080218102 Sliski et al. Sep 2008 A1
20080219407 Kaiser et al. Sep 2008 A1
20080219410 Gunzert-Marx et al. Sep 2008 A1
20080219411 Gunzert-Marx et al. Sep 2008 A1
20080237494 Beloussov et al. Oct 2008 A1
20080237495 Grozinger et al. Oct 2008 A1
20080267349 Rietzel Oct 2008 A1
20080270517 Baumann et al. Oct 2008 A1
20080272284 Rietzel Nov 2008 A1
20080290299 Hansmann et al. Nov 2008 A1
20080298550 Otto Dec 2008 A1
20080301872 Fahrig et al. Dec 2008 A1
20080315111 Sommer Dec 2008 A1
20090008575 Okazaki et al. Jan 2009 A1
20090032742 Kaiser et al. Feb 2009 A1
20090050819 Ma et al. Feb 2009 A1
20090060130 Wilkens et al. Mar 2009 A1
20090065717 Kaiser et al. Mar 2009 A1
20090069640 Rietzel et al. Mar 2009 A1
20090077209 Schneider Mar 2009 A1
20090096179 Stark et al. Apr 2009 A1
20090098145 Mata et al. Apr 2009 A1
20090101833 Emhofer et al. Apr 2009 A1
20090114847 Grozinger et al. May 2009 A1
20090140671 O'Neal, III et al. Jun 2009 A1
20090140672 Gall et al. Jun 2009 A1
20090175414 Messinger et al. Jul 2009 A1
20090189095 Flynn et al. Jul 2009 A1
20090200483 Gall et al. Aug 2009 A1
20090230327 Rietzel Sep 2009 A1
20090234237 Ross et al. Sep 2009 A1
20090242789 Tachikawa Oct 2009 A1
20090261275 Rietzel Oct 2009 A1
20090274269 Foland et al. Nov 2009 A1
20090296885 Boeh et al. Dec 2009 A1
20090309046 Balakin Dec 2009 A1
20090309047 Gunzert-Marx et al. Dec 2009 A1
20090309520 Balakin Dec 2009 A1
20090314960 Balakin Dec 2009 A1
20090314961 Balakin Dec 2009 A1
20090321656 Rietzel et al. Dec 2009 A1
20100006106 Balakin Jan 2010 A1
20100006770 Balakin Jan 2010 A1
20100008466 Balakin Jan 2010 A1
20100014639 Balakin Jan 2010 A1
20100014640 Balakin Jan 2010 A1
20100020932 Yi et al. Jan 2010 A1
20100027745 Balakin Feb 2010 A1
20100038552 Trbojevic Feb 2010 A1
20100045213 Sliski et al. Feb 2010 A1
20100046697 Balakin Feb 2010 A1
20100046713 Nord et al. Feb 2010 A1
20100060209 Balakin Mar 2010 A1
20100090122 Balakin Apr 2010 A1
20100091948 Balakin Apr 2010 A1
20100126964 Smith et al. May 2010 A1
20100127184 Balakin May 2010 A1
20100128846 Balakin May 2010 A1
20100133444 Balakin Jun 2010 A1
20100133446 Balakin Jun 2010 A1
20100141183 Balakin Jun 2010 A1
20100166150 Perkins et al. Jul 2010 A1
20100171045 Guneysel Jul 2010 A1
20100171447 Balakin Jul 2010 A1
20100176309 Mackie et al. Jul 2010 A1
20100207552 Balakin Aug 2010 A1
20100230617 Gall Sep 2010 A1
20100230620 Tsoupas et al. Sep 2010 A1
20100243911 Fujii et al. Sep 2010 A1
20100252754 Brown et al. Oct 2010 A1
20100264327 Bonig et al. Oct 2010 A1
20100266100 Balakin Oct 2010 A1
20100288945 Gnutzmann et al. Nov 2010 A1
20100296534 Levecq et al. Nov 2010 A1
20100301235 Bert et al. Dec 2010 A1
20100308235 Sliski et al. Dec 2010 A1
20100320404 Tanke Dec 2010 A1
20100327187 Beloussov et al. Dec 2010 A1
20110006214 Bonig Jan 2011 A1
20110009736 Maltz et al. Jan 2011 A1
20110011729 Poehlmann-Martins et al. Jan 2011 A1
20110027853 Bert et al. Feb 2011 A1
20110047469 Baumann et al. Feb 2011 A1
20110049396 Furth et al. Mar 2011 A1
20110051891 O'Connor et al. Mar 2011 A1
20110101236 Cameron et al. May 2011 A1
20110118529 Balakin May 2011 A1
20110118531 Balakin May 2011 A1
20110124976 Sabczynski et al. May 2011 A1
20110127443 Comer et al. Jun 2011 A1
20110147608 Balakin Jun 2011 A1
20110150180 Balakin Jun 2011 A1
20110166219 Stockfleth Jul 2011 A1
20110180720 Balakin Jul 2011 A1
20110180731 Welsh Jul 2011 A1
20110182410 Balakin Jul 2011 A1
20110186720 Jongen et al. Aug 2011 A1
20110196223 Balakin Aug 2011 A1
20110200170 Nord et al. Aug 2011 A1
20110204262 Pu et al. Aug 2011 A1
20110214588 Grubling et al. Sep 2011 A1
20110218430 Balakin Sep 2011 A1
20110220794 Censor et al. Sep 2011 A1
20110220798 Baurichter et al. Sep 2011 A1
20110231147 Takayanagi et al. Sep 2011 A1
20110233423 Balakin Sep 2011 A1
20110238440 Leuschner Sep 2011 A1
20110248188 Brusasco et al. Oct 2011 A1
20110278477 Balakin Nov 2011 A1
20110284757 Butuceanu et al. Nov 2011 A1
20110284760 Balakin Nov 2011 A1
20110285327 Begg et al. Nov 2011 A1
20110297850 Claereboudt et al. Dec 2011 A1
20110299657 Havelange et al. Dec 2011 A1
20110299919 Stark et al. Dec 2011 A1
20110303858 Bert et al. Dec 2011 A1
20110306870 Kuhn Dec 2011 A1
20110313232 Balakin Dec 2011 A1
20120001085 Fujimoto et al. Jan 2012 A1
20120043481 Mansfield et al. Feb 2012 A1
20120043482 Prince et al. Feb 2012 A1
20120056099 Behrens et al. Mar 2012 A1
20120056109 Lomax Mar 2012 A1
20120069961 Pomper et al. Mar 2012 A1
20120077748 Vidyasagar et al. Mar 2012 A1
20120099704 Ruan et al. Apr 2012 A1
20120112092 Pomper et al. May 2012 A1
20120119114 Brauer May 2012 A1
20120136194 Zhang et al. May 2012 A1
20120143051 Balakin Jun 2012 A1
20120205551 Balakin Aug 2012 A1
20120207276 Pomper et al. Aug 2012 A1
20120209109 Balakin Aug 2012 A1
20120223246 Stephani et al. Sep 2012 A1
20120224667 Cheng et al. Sep 2012 A1
20120242257 Balakin Sep 2012 A1
20120248325 Balakin Oct 2012 A1
20120256103 Luzzara Oct 2012 A1
20120264998 Fujitaka et al. Oct 2012 A1
20120267543 Noda et al. Oct 2012 A1
20120267544 Ueda Oct 2012 A1
20120273665 Schulte et al. Nov 2012 A1
20120273666 Bert et al. Nov 2012 A1
20120280150 Jongen Nov 2012 A1
20120303384 Stepaniak et al. Nov 2012 A1
20120305796 Iseki et al. Dec 2012 A1
20120313003 Trbojevic Dec 2012 A1
20120326722 Weinberg et al. Dec 2012 A1
20130001432 Jongen Jan 2013 A1
20130043403 Gordon et al. Feb 2013 A1
20130053616 Gall et al. Feb 2013 A1
20130053617 Pu et al. Feb 2013 A1
20130068938 Heese Mar 2013 A1
20130072743 Fieres et al. Mar 2013 A1
20130072744 Moskvin et al. Mar 2013 A1
20130086500 Kane et al. Apr 2013 A1
20130090549 Meltsner et al. Apr 2013 A1
20130108014 Tome et al. May 2013 A1
20130127375 Sliski et al. May 2013 A1
20130131424 Sliski et al. May 2013 A1
20130131433 Katscher et al. May 2013 A1
20130150647 Chen et al. Jun 2013 A1
20130163723 Tacke Jun 2013 A1
20130187060 Jongen Jul 2013 A1
20130208867 Beckman Aug 2013 A1
20130209450 Cohen et al. Aug 2013 A1
20130211482 Piipponen Aug 2013 A1
20130217946 Balakin Aug 2013 A1
20130217948 Mihaylov Aug 2013 A1
20130217950 Partanen et al. Aug 2013 A1
20130218009 Balakin Aug 2013 A1
20130221213 Takayanagi et al. Aug 2013 A1
20130237425 Leigh et al. Sep 2013 A1
20130237822 Gross et al. Sep 2013 A1
20130243722 Basile et al. Sep 2013 A1
20130245113 Stockfleth Sep 2013 A1
20130259335 Mallya et al. Oct 2013 A1
20130261430 Uhlemann Oct 2013 A1
20130267756 Totake et al. Oct 2013 A1
20130277569 Behrens et al. Oct 2013 A1
20130299721 Sasai Nov 2013 A1
20130303824 Stephani et al. Nov 2013 A1
20130324479 Zhang et al. Dec 2013 A1
20130345489 Beloussov et al. Dec 2013 A1
20140005463 Jongen Jan 2014 A1
20140005464 Bharat et al. Jan 2014 A1
20140014851 Asaba Jan 2014 A1
20140028220 Bromberg et al. Jan 2014 A1
20140042934 Tsutsui Feb 2014 A1
20140046113 Fujimoto et al. Feb 2014 A1
20140061493 Prieels et al. Mar 2014 A1
20140066755 Matteo et al. Mar 2014 A1
20140077699 Boswell et al. Mar 2014 A1
20140091238 Miyashita et al. Apr 2014 A1
20140091734 Gall et al. Apr 2014 A1
20140094371 Zwart et al. Apr 2014 A1
20140094637 Zwart et al. Apr 2014 A1
20140094638 Gall et al. Apr 2014 A1
20140094639 Zwart et al. Apr 2014 A1
20140094640 Gall et al. Apr 2014 A1
20140094641 Gall et al. Apr 2014 A1
20140094643 Gall et al. Apr 2014 A1
20140097920 Goldie et al. Apr 2014 A1
20140107390 Brown et al. Apr 2014 A1
20140112453 Prince et al. Apr 2014 A1
20140113388 Bitter et al. Apr 2014 A1
20140121441 Huber et al. May 2014 A1
20140128719 Longfield May 2014 A1
20140145090 Jongen May 2014 A9
20140193058 Bharat et al. Jul 2014 A1
20140200448 Schulte et al. Jul 2014 A1
20140203186 Iwamoto et al. Jul 2014 A1
20140221816 Franke et al. Aug 2014 A1
20140239204 Orton et al. Aug 2014 A1
20140257011 Spotts Sep 2014 A1
20140257099 Balakin Sep 2014 A1
20140275699 Benna et al. Sep 2014 A1
20140308202 Matusik et al. Oct 2014 A1
20140316184 Fujimoto et al. Oct 2014 A1
20140330063 Balakin Nov 2014 A1
20140332691 Campbell et al. Nov 2014 A1
20140336438 Bharat et al. Nov 2014 A1
20140350322 Schulte et al. Nov 2014 A1
20140369958 Basile Dec 2014 A1
20140371076 Jongen Dec 2014 A1
20140371511 Zwart et al. Dec 2014 A1
20150015167 Ungaro et al. Jan 2015 A1
20150030223 Pearlstein et al. Jan 2015 A1
20150031933 Yamamoto et al. Jan 2015 A1
20150041665 Hollebeek et al. Feb 2015 A1
20150076370 Totake et al. Mar 2015 A1
20150080633 Anferov Mar 2015 A1
20150080634 Huber et al. Mar 2015 A1
20150087883 Boudreau et al. Mar 2015 A1
20150087885 Boisseau et al. Mar 2015 A1
20150087887 Iwata Mar 2015 A1
20150087960 Treffert Mar 2015 A1
20150090894 Zwart et al. Apr 2015 A1
20150099917 Bula et al. Apr 2015 A1
20150099918 Takayanagi et al. Apr 2015 A1
20150126797 Aptaker et al. May 2015 A1
20150146856 Beckman May 2015 A1
20150148584 Gall et al. May 2015 A1
20150174429 Zwart et al. Jun 2015 A1
20150196534 Vidyasagar et al. Jul 2015 A1
20150196779 Tonner Jul 2015 A1
20150209601 Benna et al. Jul 2015 A1
20150217138 Fujimoto et al. Aug 2015 A1
20150217140 Balakin Aug 2015 A1
20150231411 O'Neal, III et al. Aug 2015 A1
20150273239 Hsu et al. Oct 2015 A1
20150321025 Freud et al. Nov 2015 A1
20150328483 Odawara et al. Nov 2015 A1
20150335463 De Gruytere Nov 2015 A1
20150335919 Behar et al. Nov 2015 A1
20150337393 Keller et al. Nov 2015 A1
20150343238 Balakin Dec 2015 A1
20150352372 Takayanagi et al. Dec 2015 A1
20150352374 Gattiker et al. Dec 2015 A1
20150374324 Nishimura et al. Dec 2015 A1
20160000387 Buchsbaum et al. Jan 2016 A1
20160008631 Harada et al. Jan 2016 A1
20160016010 Schulte et al. Jan 2016 A1
20160048981 Pearlstein et al. Feb 2016 A1
20160059039 Liu Mar 2016 A1
20160067316 Sunavala-Dossabhoy Mar 2016 A1
20160071623 Schewiola et al. Mar 2016 A1
20160074675 Moskvin et al. Mar 2016 A1
20160113884 Lin et al. Apr 2016 A1
20160136457 Jung et al. May 2016 A1
20160144201 Schulte May 2016 A1
20160172066 Claereboudt Jun 2016 A1
20160172067 Claereboudt et al. Jun 2016 A1
20160175052 Kumar et al. Jun 2016 A1
20160175617 Spatola et al. Jun 2016 A1
20160199667 Flynn Jul 2016 A1
20160199670 Michaud et al. Jul 2016 A1
20160199671 Jongen Jul 2016 A1
20160220846 Matteo et al. Aug 2016 A1
20160220847 Benna et al. Aug 2016 A1
20160243232 Pickett Aug 2016 A1
20160250501 Balakin Sep 2016 A1
20160250503 Balakin et al. Sep 2016 A1
20160256712 Vahala et al. Sep 2016 A1
20160263404 Mougenot Sep 2016 A1
20160270203 Ungaro et al. Sep 2016 A1
20160271424 Lee et al. Sep 2016 A1
20160287899 Park et al. Oct 2016 A1
20160296766 El Fakhri et al. Oct 2016 A1
20160303399 Balakin Oct 2016 A1
20160331999 Hartman et al. Nov 2016 A1
20170128746 Zwart May 2017 A1
20170157422 Zwart et al. Jun 2017 A1
20170157424 Zwart et al. Jun 2017 A1
20170157425 Zwart et al. Jun 2017 A1
20170182338 Zwart et al. Jun 2017 A1
Foreign Referenced Citations (167)
Number Date Country
2629333 May 2007 CA
1377521 Oct 2002 CN
1537657 Oct 2004 CN
1816243 Aug 2006 CN
101061759 Oct 2007 CN
101145409 Mar 2008 CN
101361156 Feb 2009 CN
101932361 Dec 2010 CN
101933405 Dec 2010 CN
101933406 Dec 2010 CN
102905761 Jan 2013 CN
2753397 Jun 1978 DE
3148100 Jun 1983 DE
3530446 Mar 1986 DE
3711245 Oct 1988 DE
4101094 May 1992 DE
4411171 Oct 1995 DE
19907098 Aug 2000 DE
102011089235 Aug 2012 DE
0194728 Sep 1986 EP
0208163 Jan 1987 EP
0221987 May 1987 EP
0222786 May 1987 EP
0277521 Aug 1988 EP
0306966 Mar 1989 EP
0388123 Sep 1990 EP
0465597 Jan 1992 EP
0499253 Aug 1992 EP
0751532 Jan 1997 EP
0776595 Jun 1997 EP
0864337 Sep 1998 EP
0911064 Apr 1999 EP
1069809 Jan 2001 EP
1153398 Nov 2001 EP
1294445 Mar 2003 EP
1348465 Oct 2003 EP
1358908 Nov 2003 EP
1371390 Dec 2003 EP
1402923 Mar 2004 EP
1430932 Jun 2004 EP
1454653 Sep 2004 EP
1454654 Sep 2004 EP
1454655 Sep 2004 EP
1454656 Sep 2004 EP
1454657 Sep 2004 EP
1477206 Nov 2004 EP
1605742 Dec 2005 EP
1738798 Jan 2007 EP
1826778 Aug 2007 EP
1949404 Jul 2008 EP
2114529 Nov 2009 EP
2183753 May 2010 EP
2227295 Sep 2010 EP
2232961 Sep 2010 EP
2232962 Sep 2010 EP
2363170 Sep 2011 EP
2363171 Sep 2011 EP
2394498 Dec 2011 EP
2514482 Oct 2012 EP
2524718 Nov 2012 EP
3035776 Jun 2016 EP
3088048 Nov 2016 EP
2560421 Aug 1985 FR
2911843 Aug 2008 FR
0957342 May 1964 GB
2015821 Sep 1979 GB
2361523 Oct 2001 GB
S47-028762 Dec 1972 JP
S48-108098 Dec 1973 JP
S57-162527 Oct 1982 JP
58-141000 Aug 1983 JP
S61-80800 Apr 1986 JP
61-225798 Oct 1986 JP
62-150804 Jul 1987 JP
62-186500 Aug 1987 JP
63-149344 Jun 1988 JP
63-218200 Sep 1988 JP
63-226899 Sep 1988 JP
64-89621 Apr 1989 JP
01-276797 Nov 1989 JP
01-302700 Dec 1989 JP
4-94198 Mar 1992 JP
H06-036893 Feb 1994 JP
H06-233831 Aug 1994 JP
07-260939 Oct 1995 JP
07-263196 Oct 1995 JP
08-173890 Jul 1996 JP
08-264298 Oct 1996 JP
09-162585 Jun 1997 JP
10-071213 Mar 1998 JP
11-47287 Feb 1999 JP
H1128252 Feb 1999 JP
11-102800 Apr 1999 JP
11-243295 Sep 1999 JP
2000-243309 Sep 2000 JP
2000-294399 Oct 2000 JP
2001-6900 Jan 2001 JP
2001-009050 Jan 2001 JP
2001-129103 May 2001 JP
2001-276238 Oct 2001 JP
2001-346893 Dec 2001 JP
2002-164686 Jun 2002 JP
2003-504628 Feb 2003 JP
2003-517755 May 2003 JP
2004-031115 Jan 2004 JP
2005-526578 Sep 2005 JP
2006-032282 Feb 2006 JP
2006341010 Dec 2006 JP
2007-307223 Nov 2007 JP
2008-068092 Mar 2008 JP
2008-507826 Mar 2008 JP
04-128717 Jul 2008 JP
04-129768 Aug 2008 JP
2009-515671 Apr 2009 JP
2009-516905 Apr 2009 JP
04-273409 Jun 2009 JP
04-337300 Sep 2009 JP
43-23267 Sep 2009 JP
2010-536130 Nov 2010 JP
2011-505191 Feb 2011 JP
2011-505670 Feb 2011 JP
2011-507151 Mar 2011 JP
05-046928 Oct 2012 JP
2012-223259 Nov 2012 JP
2013-106981 Jun 2013 JP
05-341352 Nov 2013 JP
300137 Jun 1969 SU
569635 Aug 1977 SU
200930160 Jul 2009 TW
200934682 Aug 2009 TW
200939908 Sep 2009 TW
200940120 Oct 2009 TW
WO-8607229 Dec 1986 WO
WO-9012413 Oct 1990 WO
WO-9203028 Feb 1992 WO
WO-9302536 Feb 1993 WO
WO-9817342 Apr 1998 WO
WO-199939385 Aug 1999 WO
WO-200040064 Jul 2000 WO
WO-200049624 Aug 2000 WO
WO-01126569 Apr 2001 WO
WO-2001026230 Apr 2001 WO
WO-0207817 Jan 2002 WO
WO-2003039212 May 2003 WO
WO-2003092812 Nov 2003 WO
WO-2004026401 Apr 2004 WO
WO-2004101070 Nov 2004 WO
WO-2006-012467 Feb 2006 WO
WO-2007061937 May 2007 WO
WO-2007084701 Jul 2007 WO
WO-2007130164 Nov 2007 WO
WO-2007145906 Dec 2007 WO
WO-2008030911 Mar 2008 WO
WO-2008081480 Jul 2008 WO
WO-2009048745 Apr 2009 WO
WO-2009070173 Jun 2009 WO
WO-2009070588 Jun 2009 WO
WO-2009073480 Jun 2009 WO
WO-2014018706 Jan 2014 WO
WO-2014018876 Jan 2014 WO
WO-2015003111 Jan 2015 WO
WO-2015095678 Jun 2015 WO
WO-2015107660 Jul 2015 WO
WO-2016201348 Dec 2016 WO
WO-2017082984 May 2017 WO
WO-2018128822 Jul 2018 WO
WO-2019006253 Jan 2019 WO
Non-Patent Literature Citations (285)
Entry
18th Japan Conference on Radiation and Radioisotopes [Japanese], Nov. 25-27, 1987, 9 pages.
510(k) Summary: Ion Beam Applications S.A., FDA, Jul. 12, 2001, 5 pages.
510(k) Summary: Optivus Proton Beam Therapy System, Jul. 21, 2000, 5 pages.
Abrosimov et al., 1000MeV Proton Beam Therapy facility at Petersburg Nuclear Physics Institute Synchrocyclotron, Medical Radiology (Moscow) 32, 10 (1987) revised in Journal of Physics, Conference Series 41, 2006, pp. 424-432, Institute of Physics Publishing Limited.
Abrosimov et al., Neutron Time-of-flight Spectrometer Gneis at the Gatchina 1 GeV Protron Syncrhocyclotron, Mar. 9, 1985 and revised form Jul. 31, 1985, Lemingrad Nuclear Physics Institute, Gatchina, 188350, USSR (15 pages).
Adachi et al., A 150MeV FFAG Synchrotron with Return-Yoke Free Magent, Proceedings of the 2001 Particle Accelerator Conference, Chicago, 2001, 3 pages.
Ageyev et al., The IHEP Accelerating and Storage Complex (UNK) Status Report, 11th International Conference on High-Energy Accelerators, 1980, pp. 60-70.
Agosteo et al., Maze Design of a gantry room for proton therapy, Nuclear Instruments & Methods in Physics Research, 1996, Section A, 382, pp. 573-582.
Alexeev et al., R4 Design of Superconducting Magents for Proton Synchrotrons, Proceedings of the Fifth International Cryogenic Engineering Conference, 197 4, pp. 531-533.
Allardyce et al., Performance and Prospects of the Reconstructed CERN 600 MeV Synchrocyclotron, IEEE Transactions on Nuclear Science USA, Jun. 1977, ns-24:(3) 1631-1633.
Alonso, Magnetically Scanned Ion Beams for Radiation Therapy, Accelerator & Fusion Research Division, Lawrence Berkeley Laboratory, Berkeley, CA, Oct. 1988, 13 pages.
Amaldi et al., The Italian project for a hadrontherapy centre Nuclear Instruments and Methods in Physics Research A, 1995, 360, pp. 297-301.
Amaldi, Overview of the world landscape of Hadrontherapy and the projects of the TERA foundation, Physica Medica, An International journal Devoted to the Applications of Physics to Medicine and Biology, Jul. 1998, vol. XIV, Supplement 1, 6th Workshop on Heavy Charged Particles in Biology and Medicine, Instituto Scientific Europeo (ISE), Sep. 29-Oct. 1, 1977, Baveno, pp. 76-85.
An Accelerated Collaboration Meets with Beaming Success, Lawrence Livermore National Laboratory, Apr. 12, 2006, S&TR, Livermore, California, pp. 1-3, http://www.llnl.gov/str/April06/Caporaso.html.
Anferov et al., Status of the Midwest Proton Radiotherapy Institute, Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 699-701.
Anferov et al., The Indiana University Midwest Proton Radiation Institute, Proceedings of the 2001 Particle Accelerator Conference, 2001, Chicago, pp. 645-647.
Appun, Various problems of magnet fabrication for high-energy accelerators, Journal for All Engineers Interested in the Nuclear Field, 1967, 11 pages 10-16 (1967) [Lang.: German], English bibliographic information (httn://www.osti.1mv/enernvcitations/nroduct.biblio.isn?ostiid=4442292).
Arduini et al. Physical specifications of clinical proton beams from a synchrotron, Med. Phys, Jun. 1996, 23 ( 6): 939-951.
Badano et al., Proton-Ion Medical Machine Study (PIMMS) Part I, PIMMS, Jan. 1999, 238 pages.
Beam Delivery and Properties, Journal of the ICRU, 2007, 7(2):20 pages.
Beeckman et al., Preliminary design of a reduced cost proton therapy facility using a compact, high field isochronous cyclotron, Nuclear Instruments and Methods in Physics Research B56/57, 1991, pp. 1201-1204.
Bellomo et al., The Superconducting Cyclotron Program at Michigan State University, Bulletin of the American Physical Society, Sep. 1980, 25(7):767.
Benedikt and Carli, Matching to Gantries for Medical Synchrotrons IEEE Proceedings of the 1997 Particle Accelerator Conference, 1997, pp. 13 79-13 81.
Bieth et al., A Very Compact Protontherapy Facility Based on an Extensive Use of High Temperature Superconductors (HTS) Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Jun. 14-19, 1998, pp. 669-672.
Bigham, Magnetic Trim Rods for Superconducting Cyclotrons, Nuclear Instruments and Methods (North-Holland Publishing Co.), 1975, 141:223-228.
Bimbot, First Studies of the External Beam from the Orsay S.C. 200 MeV, Institut de Physique Nucleaire, BP 1, Orsay, France, IEEE, 1979, pp. 1923-1926.
Blackmore et al., Operation of the Triumf Proton Therapy Facility, IEEE Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 3:3831-3833.
Bloch, The Midwest Proton Therapy Center, Application of Accelerators in Research and Industry, Proceedings of the Fourteenth Int'l. Conf, Part Two, Nov. 1996, pp. 1253-1255.
Blosser et al., A Compact Superconducting Cyclotron for the Production of High Intensity Protons, Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, 1:1054-1056.
Blosser et al., Advances in Superconducting Cyclotrons at Michigan State University, Proceedings of the 11th International Conference on Cyclotrons and their Applications, Oct. 1986, pp. 157-167, Tokyo.
Blosser et al., Characteristics of a 400 (Q2/A) MeV Super-Conducting Heavy-Ion Cyclotron, Bulletin of the American Physical Society, Oct. 1974, p. 1026.
Blosser et al., Medical Accelerator Projects at Michigan State Univ. IEEE Proceedings of the 1989 Particle Accelerator Conference, Mar. 20-23, 1989, 2:742-746.
Blosser et al., Problems and Accomplishments of Superconducting Cyclotrons, Proceedings of the 14th International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 674-684.
Blosser et al., Superconducting Cyclotron for Medical Application, IEEE Transactions on Magnetics, Mar. 1989, 25(2): 1746-1754.
Blosser et al., Superconducting Cyclotrons, Seventh International Conference on Cyclotrons and their Applications, Aug. 19-22, 1975, pp. 584-594.
Blosser, Application of Superconductivity in Cyclotron Construction, Ninth International Conference on Cyclotrons and their Applications, Sep. 1981, pp. 147-157.
Blosser, Applications of Superconducting Cyclotrons, Twelfth International Conference on Cyclotrons and Their Applications, May 8-12, 1989, pp. 137-144.
Blosser, Future Cyclotrons, AIP, The Sixth International Cyclotron Conference, 1972, pp. 16-32.
Blosser, H., Present and Future Superconducting Cyclotrons, Bulletin of the American Physical Society, Feb. 1987, 32(2):171 Particle Accelerator Conference, Washington, D.C.
Blosser, H.G., Superconducting Cyclotrons at Michigan State University, Nuclear Instruments & Methods in Physics Research, 1987,vol. B 24/25, part II, pp. 752-756.
Blosser, Medical Cyclotrons, Physics Today, Special Issue Physical Review Centenary, Oct. 1993, pp. 70-73.
Blosser, Preliminary Design Study Exploring Building Features Required for a Proton Therapy Facility for the Ontario Cancer Institute, Mar. 1991, MSUCL-760a, 53 pages.
Blosser, Progress on the Coupled Superconducting Cyclotron Project, Bulletin of the American Physical Society, 1993 (p. 3).
Blosser, Synchrocyclotron Improvement Programs, IEEE Transactions on Nuclear Science USA, Jun. 1969, 16(3):Part I, pp. 405-414.
Blosser, The Michigan State University Superconducting Cyclotron Program, Nuclear Science, Apr. 1979, NS-26(2):2040-2047.
Botha et al., A New Multidisciplinary Separated-Sector Cyclotron Facility, IEEE Transactions on Nuclear Science, 1977, NS-24(3): 1118-1120.
Boyer, A. et al., Basic Applications of Multi-leaf Collimators: Report of Task Group No. 50-Radiation Therapy Committee, AAPM Report No. 72, American Association of Physicists in Medicine by Medical Physics Publishing, 62 pages (2001).
Bues, M. et al., Therapeutic Step and Shoot Proton Beam Spot-Scanning With a Multi-Leaf Collimator: A Monte Carlo Study, Radiation Protection Dosimetry, 115(1-4):164-169 (2005).
Chichili et al., Fabrication ofNb3Sn Shell-Type Coils with Pre-Preg Ceramic Insulation, American Institute of Physics Conference Proceedings, AIP USA, No. 711, (XP-002436709, ISSN: 0094-243X), 2004, pp. 450-457.
Chong et al., Radiology Clinic North American 7, 3319, 1969, 27 pages.
Chu et al., Instrumentation for Treatment of Cancer Using Proton and Light-ion Beams, Review of Scientific Instruments, Aug. 1993, 64 (8):2055-2122.
Chu et al., Performance Specifications for Proton Medical Facility, Lawrence Berkeley Laboratory, University of California, Mar. 1993, 128 pages.
Chu, Instrumentation in Medical Systems, Accelerator and Fusion Research Division, Lawrence Berkeley Laboratory, University of California, Berkeley, CA, May 1995, 9 pages.
Cole et al., Design and Application of a Proton Therapy Accelerator, Fermi National Accelerator Laboratory, IEEE, 1985, 5 pages.
Collins, et al., The Indiana University Proton Therapy System, Proceedings of EPAC 2006, Edinburgh, Scotland, 2006, 3 pages.
Communication pursuant to Article 94(3) EPC for EP14830919.8, 6 pages (May 12, 2017).
Communication pursuant to Rules 161(1) and 162 EPC in EP14830919.8, 2 pages (Sep. 2, 2016).
Communication under Rule 71(3) EPC for EP14830919.8, 113 pages (May 2, 2018).
Conradi et al., Proposed New Facilities for Proton Therapy at iThemba Labs, Proceedings of EPAC, 2002, pp. 560-562.
C/E Source of Ions for Use in Sychro-Cyclotrons Search, Jan. 31, 2005, 9 pages.
Cosgrove et al., Microdosimetric Studies on the Orsay Proton Synchrocyclotron at 73 and 200 MeV, Radiation Protection Dosimetry, 1997, 70(1-4):493-496.
Coupland, High-field (5 T) pulsed superconducting dipole magnet, Proceedings of the Institution of Electrical EnRineers, Jul. 1974, 121(7):771-778.
Coutrakon et al. Proton Synchrotrons for Cancer Therapy, Application of Accelerators in Research and Industry—Sixteenth International Conf., American Institute of Physics, Nov. 1-5, 2000, vol. 576, pp. 861-864.
Coutrakon et al., A prototype beam delivery system for the proton medical accelerator at Loma Linda, Medical Physics, Nov./Dec. 1991, 18(6):1093-1099.
CPAC Highlights Its Proton Therapy Program at ESTRO Annual Meeting, TomoTherapy Incorporated, Sep. 18, 2008, Madison, Wisconsin, pp. 1-2.
Cuttone, Applications of a Particle Accelerators in Medical Physics, Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud, V.S. Sofia, 44 Cantania, Italy, Jan. 2010, 17 pages.
Daartz, J. et al., Characterization of a mini-multileaf collimator in a proton beamline, Med. Phys., 36(5):9 pages (2009).
Dahl P, Superconducting Magnet System, American Institute of Physics, AIP Conference Proceedings, 1987-1988, 2: 1329-1376.
Dialog Search, Jan. 31, 2005, 17 pages.
Dugan et al., Tevatron Status IEEE, Particle Accelerator Conference, Accelerator Science & Technology, 1989, pp. 426-430.
Eickhoff et al., The Proposed Accelerator Facility for Light Ion Cancer Therapy in Heidelberg, Proceedings of the 1999 Particle Accelerator Conference, New York, 1999, pp. 2513-2515.
Enchevich et al., Minimizing Phase Losses in the 680 MeV Synchrocyclotron by Correcting the Accelerating Voltage Amplitude, Atomnaya Energiya, 1969, 26:(3):315-316.
Endo et al., Compact Proton and Carbon Ion Synchrotrons for Radiation Therapy, Proceedings of EPAC 2002, Paris France, 2002, pp. 2733-2735.
File History of U.S. Appl. No. 13/303,110.
File History of U.S. Appl. No. 61/843,092, 84 pages (downloaded Oct. 14, 2016).
File History of U.S. Appl. No. 61/900,455, 43 pages (downloaded Oct. 14, 2016).
File History of U.S. Appl. No. 61/946,074, 137 pages (downloaded Oct. 14, 2016).
Final Office Action for U.S. Appl. No. 14/937,048, 52 pages (dated Mar. 1, 2018).
Final Office Action for U.S. Appl. No. 15/438,544, 31 pages (dated Mar. 1, 2018).
Final Office Action for U.S. Appl. No. 14/137,854, 29 pages (dated Sep. 19, 2016).
First Office Action (English translation) for JP2016-541203, 10 pages (dated Jul. 31, 2017).
First Office Action (Japanese translation) for JP2016-541203, 7 pages (dated Jul. 31, 2017).
First Office Action for CN201480070002.6 (Chinese translation), 9 pages (dated Apr. 11, 2018).
First Office Action for CN201480070002.6 (English translation), 12 pages (dated Apr. 11, 2018).
Flanz et al., Large Medical Gantries, Particle Accelerator Conference, Massachusetts General Hospital, 1995, pp. 1-5.
Flanz et al., Operation of a Cyclotron Based Proton Therapy Facility, Massachusetts General Hospital, Boston, MA 02114, pp. 1-4, retrieved from Internet in 2009.
Flanz et al., The Northeast Proton Therapy Center at Massachusetts General Hospital, Fifth Workshop on Heavy Charge Particles in Biology and Medicine, GSI, Darmstadt, Aug. 1995, 11 pages.
Flanz et al., Treating Patients with the NPTC Accelerator Based Proton Treatment Facility, Proceedings of the 2003 Particle Accelerator Conference, 2003, pp. 690-693.
Flood and Frazier, The Wide-Band Driven RF System for the Berkeley 88-Inch Cyclotron, American Institute of Physics, Conference Proceedings., No. 9, 1972, 459-466.
Foster and Kashikhin, Superconducting Superferric Dipole Magent with Cold Iron Core for the VLHC, IEEE Transactions on Applied Superconductivity, Mar. 2002, 12(1):111-115.
Fredriksson, Albin, Robust optimization of radiation therapy accounting for geometric uncertainty, Doctoral Thesis, 57 pages (2013).
Friesel et al., Design and Construction Progress on the IUCF Midwest Proton Radiation Institute, Proceedings of EPAC 2002, 2002, pp. 2736-2738.
Fukumoto et al., A Proton Therapy Facility Plan Cyclotrons and their Applications, Proceedings of the 13th International Conference, Vancouver, Canada, Jul. 6-10, 1992, pp. 258-261.
Fukumoto, Cyclotron Versus Synchrotron for Proton Beam Therapy, KEK Prepr., No. 95-122, Oct. 1995, pp. 533-536.
Gelover, E. et al., A method for modeling laterally asymmetric proton beamlets resulting from collimation, Medical Physics, 42:1321-1334 (2015).
Goto et al., Progress on the Sector Magnets for the Riken SRC, American Institute of Physics, 714 CP600, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 319-323.
Graffman et al., Design Studies for a 200 MeV Proton Clinic for Radiotherapy, AIP Conference Proceedings: Cyclotrons—1972, 1972, No. 9, pp. 603-615.
Graffman, et. al. Proton radiotherapy with the Uppsala cyclotron. Experience and plans Strahlentherapie, 1985, 161(12):764-770.
Graffman, S., et al., Clinical Trials in Radiotherapy and the Merits of High Energy Protons, Acta Radiol. Therapy Phys. Biol. 9:1-23 (1970).
Hede, Research Groups Promoting Proton Therapy Lite, Journal of the National Cancer Institute, Dec. 6, 2006, 98(23):1682-1684.
Heinz, Superconducting Pulsed Magnetic Systems for High-Energy Synchrotrons, Proceedings of the Fourth International Cryogenic Engineering Conference, May 24-26, 1972, pp. 55-63.
Hentschel et al., Plans for the German National Neutron Therapy Centre with a Hospital-Based 70 MeV Proton Cyclotron at University Hospital Essen/Germany, Cyclotrons and their Applications, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Caen, Franco, Jun. 14-19, 1998, pp. 21-23.
Hepburn et al., Superconducting Cyclotron Neutron Source for Therapy, International Journal of Radiation Oncology Biology Physics, vol. 3 complete, 1977, pp. 387-391.
Hirabayashi, Development of Superconducting Magnets for Beam Lines and Accelerator at KEK, IEEE Transaction on Magnetics, Jan. 1981, Mag-17(1 ):728-731.
Hyer, D. et al., A dynamic collimation system for penumbra reduction in spot-scanning proton therapy: Proof of concept; Medical Physics, 41(9):091701-1-091701-9 (2014).
Indiana's mega-million proton therapy cancer center welcomes its first patients [online] Press release, Health & Medicine Week, 2004, retrieved from NewsRx.com, Mar. 1, 2004, pp. 119-120.
International Preliminary Report on Patentability for PCT/US2014/071448, 14 pages (dated Jun. 30, 2016).
International Search Report and Written Opinion issued in corresponding PCT application No. PCT/US2014/071448 dated Jul. 24, 2015 (18 pages).
International Search Report for PCT/US2016/048037, 11 pages (dated Feb. 6, 2017).
International Search Report for PCT/US2017/067677 (High-Speed Energy Switching, filed Dec. 20, 2017), issued by ISA/US, 4 pages (dated Apr. 30, 2018).
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2014/071448 dated Apr. 13, 2015 (11 pages).
Invitation to Pay Additional Fees and, where applicable, protest fee issued in PCT application PCT/US2016/048037 dated Oct. 20, 2016 (8 pages).
Ishibashi and Mcinturff, Stress Analysis of Superconducting 1 OT Magnets for Synchrotron, Proceedings of the Ninth International Cryogenic Engineering Conference, May 11-14, 1982, pp. 513-516.
Ishibashi and Mcinturff, Winding Design Study of Superconducting 10 T Dipoles for a Synchrotron, IEEE Transactions on Magentics, May 1983, MAG-19(3):1364-1367.
Jahnke et al., First Superconducting Prototype Magnets for a Compact Synchrotron Radiation Source in Operation, IEEE Transactions on Magnetics, Mar. 1988, 24(2):1230-1232.
Jones and Dershem, Synchrotron Radiation from Proton in a 20 TEV, 10 TESLA Superconducting Super Collider Proceedings of the 12th International Conference on High-Energy Accelerator, Aug. 11-16, 1983, pp. 138-140.
Jones and Mills, The South African National Accelerator Centre: Particle Therapy and Isotope Production Programmes, Radiation Physics and Chemistry, Apr.-Jun. 1998, 51 ( 4-6):571-578.
Jones et al., Status Report of the NAC Particle Therapy Programme, Stralentherapie und Onkologie, vol. 175, Suppl. II, Jun. 1999, pp. 30-32.
Jones, Present Status and Future Trends of Heavy Particle Radiotherapy, Cyclotrons and their Applications 1998, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 14-19, 1998, pp. 13-20.
Jones, Progress with the 200 MeV Cyclotron Facility at the National Accelerator Centre, Commission of the European Communities Radiation Protection Proceedings, Fifth Symposium on Neutron Dosimetry, Sep. 17-21, 1984, vol. II, pp. 989-998.
Jongen et al., Development of a Low-cost Compact Cyclotron System for Proton Therapy, National Institute of Radiol. Sci,1991, No. 81, DD. 189-200.
Jongen et al., Progress report on the IBA-SHI small cyclotron for cancer therapy Nuclear Instruments and Methods in Physics Research, Section B, vol. 79, issue 1-4, 1993, pp. 885-889.
Jongen et al., The proton therapy system for MGH's NPTC: equipment description and progress report, Bulletin du Cancer/Radiotherapie, Proceedings of the meeting of the European Heavy Particle Therapy Group, 1996, 83(Suppl. 1):219-222.
Jongen et al., The proton therapy system for the NPTC: Equipment Description and progress report, Nuclear Instruments and methods in physics research, 1996, Section B, 113(1 ): 522-525.
Kanai et al., Three-dimensional Beam Scanning for Proton Therapy, Nuclear Instruments and Methods in Physic Research, Sep. 1, 1983, The Netherlands, 214(23):491-496.
Karlin et al., Medical Radiology (Moscow), 1983, 28, 13.
Karlin et al., The State and Prospects in the Development of the Medical Proton Tract on the Synchrocyclotron in Gatchina, Med. Radial., Moscow, 28(3):28-32 (Mar. 1983)(German with English Abstract on end of p. 32).
Kats and Druzhinin, Comparison of Methods for Irradiation Prone Patients, Atomic Energy, Feb. 2003, 94(2): 120-123.
Kats and Onosovskii, A Planar Magnetooptical System for the Irradiation of a Lying Patient with a Proton Beam from Various Directions, Instruments and Experimental Techniques, 1996, 39(1):127-131.
Kats and Onosovskii, A Simple, Compact, Flat System for the Irradiation of a Lying Patient with a Proton Beam from Different Directions, Instruments and Experimental Techniques, 1996, 39(1):132-134.
Khoroshkov et al., Moscow Hospital-Based Proton Therapy Facility Design, Am. Journal Clinical Oncology: CCT, Apr. 1994, 17(2):109-114.
Kim and Blosser, Optimized Magnet for a 250 MeV Proton Radiotherapy Cyclotron, Cyclotrons and Their Applications 2001, May 2001, Sixteenth International Conference, pp. 345-347.
Kim and Yun, A Light-Ion Superconducting Cyclotron System for Multi-Disciplinary Users, Journal of the Korean Physical Society, Sep. 2003, 43(3):325-331.
Kim et al., Construction of 8T Magnet Test Stand for Cyclotron Studies, IEEE Transactions on Applied Superconductivity, Mar. 1993, 3(1):266-268.
Kim et al., Design Study of a Superconducting Cyclotron for Heavy Ion Therapy, Cyclotrons and Their Applications 2001, Sixteenth International Conference, May 13-17, 2001, pp. 324-326.
Kim et al., Trim Coil System for the Riken Cyclotron Ring Cyclotron, Proceedings of the 1997 Particle Accelerator Conference, IEEE, Dec. 1981, vol. 3, pp. 214-235 or 3422-3424, 1998.
Kim, An Eight Tesla Superconducting Magnet for Cyclotron Studies, Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1994, 13 8 pages.
Kimstrand, Beam Modelling for Treatment Planning of Scanned Proton Beams, Digital Comprehensive Summaries of Uppsala dissertations from the Faculty of Medicine 330, Uppsala Universitet, 2008, 58 pages.
Kishida and Yano, Beam Transport System for the RIKEN SSC (II), Scientific Papers of the Institute of Physical and Chemical Research, Dec. 1981, 75(4):214-235.
Koehler et al., Range Modulators for Protons and Heavy Ions, Nuclear Instruments and Methods, 1975, vol. 131, pp. 437-440.
Koto and Tsujii, Future of Particle Therapy, Japanese Journal of Cancer Clinics, 2001, 47(1):95-98 [Lang.: Japanese], English abstract (http://sciencelinks.j12/jeast/article/200206/000020020601A05 I I 453 .nhn).
Kraft et al., Hadrontherapy in Oncology, U. Amaldi and Larrsson, editors Elsevier Science, 1994, 161 pages.
Krevet et al., Design of a Strongly Curved Superconducting Bending Magnet for a Compact Synchrotron Light Source, Advances in Cryogenic Engineering, 1988, vol. 33, pp. 25-32.
Laisne et al., The Orsay 200 MeV Synchrocyclotron, IEEE Transactions on Nuclear Science, Apr. 1979, NS-26(2):1919-1922.
Larsson, B., et al., “The High-Energy Proton Beam as a Neurosurgical Tool,” Nature vol. 182, pp. 1222-1223 (1958).
Larsson, Biomedical Program for the Converted 200-MeV Synchrocyclotron at the Gustaf Werner Institute, Radiation Research, 1985, 104:S310-S318.
Lawrence et al., Heavy particles in acromegaly and Cushing's Disease, in Endocrine and Norendocrine Hormone Producing Tumors (Year Book Medical Chicago, 1973, pp. 29-61.
Lawrence et al., Successful Treatment of Acromegaly: Metabolic and Clinical Studies in 145 Patients, The Journal of Clinical Endrocrinology and Metabolism, Aug. 1970, 31(2), 21 pages.
Lawrence et al., Treatment of Pituitary Tumors, (Excerpta medica, Amsterdam/American Elsevier, New York, 1973, pp. 253-262.
Lawrence, J.H., Proton Irradiation of the Pituitary Cancer, vol. 10, pp. 795-798 (1957).
Lecroy et al., Viewing Probe for High Voltage Pulses, Review of Scientific Instruments USA, Dec. 1960, 31(12):1354.
Lin et al., Principles and 10 Year Experience of the Beam Monitor System at the PSI Scanned Proton Therapy Facility, Center for Proton Radiation Therapy, Paul Scherrer Institute, CH-5232, Villigen PSI, Switzerland, 2007, 21 pages.
Linfoot et al., Acromegaly, in Hormonal Proteins and Peptides, edited by C.H. Li, 1975, pp. 191-246.
Literature Author and Keyword Search, Feb. 14, 2005, 44 pages.
Literature Keyword Search, Jan. 24, 2005, 98 pages.
Literature Search and Keyword Search for Synchrocyclotron, Jan. 25, 2005, 68 pages.
Literature Search by Company Name/Component Source, Jan. 24, 2005, 111 pages.
Literature Search, Jan. 26, 2005, 37 pages.
Livingston, M.S., et al. A Capillary Ion Source for the Cyclotron, Review Science Instruments, vol. 10, p. 9. 63-67, (1939).
LLNL, UC Davis Team Up to Fight Cancer, Lawrence Livermore National Laboratory, Apr. 28, 2006, SF-06-04-02, Livermore, California, pp. 1-4.
Machine translation of JP11-028252A from jpo website Jul. 17, 2015.
Mandrillon, High Energy Medical Accelerators, EPAC 90, 2nd European Particle Accelerator Conference, Jun. 12-16, 1990, 2:54-58.
Marchand et al., IBA Proton Pencil Beam Scanning: an Innovative Solution for Cancer Treatment, Proceedings of EP AC 2000, Vienna, Austria, 3 pages.
Marti et al., High Intensity Operation of a Superconducting Cyclotron, Proceedings of the I 4the International Conference, Cyclotrons and Their Applications, Oct. 1995, pp. 45-48 (Oct. 1995).
Martin, Operational Experience with Superconducting Synchrotron Magnets Proceedings of the 1987 IEEE Particle Accelerator Conference, Mar. 16-19, 1987, vol. 3 of 3: 1379-1382.
Meote et al., ETOILE Hadrontherapy Project, Review of Design Studies Proceedings of EPAC 2002, 2002, pp. 2745-2747.
Miyamoto et al., Development of the Proton Therapy System, The Hitachi Hyoron, 79(10):775-775 779 (1997) [Lang: Japanese].
Moignier, A. et al., Toward improved target conformity for two spot scanning proton therapy delivery systems using dynamic collimation, Medical Physics, 43:1421-1427 (2014).
Montelius et al., The Narrow Proton Beam Therapy Unit at the Svedberg Laboratory in Uppsala, ACTA Oncologica, 1991, 30:739-745.
Moser et al., Nonlinear Beam Optics with Real Fields in Compact Storage Rings, Nuclear Instruments & Methods in Physics Research/Section B, B30, Feb. 1988, No. 1, pp. 105-109.
Moyers et al., A Continuously Variable Thickness Scatterer for Proton Beams Using Self-compensating Dual Linear Wedges Loma Linda University Medical Center, Dept. of Radiation Medicine, Loma Linda, CA, Nov. 2, 1992, 21 pages.
National Cancer Institute Funding (Senat—Sep. 21, I 992} (wvw.tbomas.loc.gov/cgibin/querv/z?rl02:S21SE2-7l2 (2 pages).
Nicholson, Applications of Proton Beam Therapy, Journal of the American Society of Radiologic Technologists, May/Jun. 1996, 67(5): 439-441.
Nolen et al., The Integrated Cryogenic—Superconducting Beam Transport System Planned for MSU, Proceedings of the J21h International Conference on High-Energy Accelerators, Aug. 1983, pp. 549-551.
Norimine et al., A Design of a Rotating Gantry with Easy Steering for Proton Therapy, Proceedings of EPAC 2002, 2002, pp. 2751-2753.
Office Action for U.S. Appl. No. 14/137,854, 24 pages (dated Oct. 23, 2017).
Office Action for U.S. Appl. No. 14/137,854, 32 pages (dated Dec. 22, 2016).
Office Action for U.S. Appl. No. 14/937,048, 56 pages (dated Aug. 15, 2018).
Office Action for U.S. Appl. No. 14/937,048, 94 pages (dated Oct. 13, 2017).
Office Action for U.S. Appl. No. 15/399,250, 78 pages (dated Jan. 19, 2018).
Office Action for U.S. Appl. No. 15/438,544, 27 pages (dated Oct. 12, 2017).
Office Action for U.S. Appl. No. 14/137,854, 39 pages (dated Apr. 5, 2017).
Ogino, Takashi, Heavy Charged Particle Radiotherapy-Proton Beam, Division of Radiation Oncology, National Cancer Hospital East, Kashiwa, Japan, Dec. 2003, 7 pages.
Okumura et al., Overview and Future Prospect of Proton Radiotherapy, Japanese Journal of Cancer Clinics, 1997, 43(2):209-214 [Japanese, English Overview on p. 3].
Okumura et al., Proton Radiotherapy Japanese Journal of Cancer and Chemotherapy, 1993, 10. 20(14):2149-2155 [Japanese, English Abstract on p. 1].
Outstanding from Search Reports, Accelerator of Polarized Portons at Fermilab, 2005, 20 pages.
Paganetti et al., Proton Beam Radiotherapy—The State of the Art, Springer Verlag, Heidelberg, ISBN 3-540-00321-5, Oct. 2005,36 pages.
Palmer and Tollestrup, Superconducting Magnet Technology for Accelerators, Annual Review of Nuclear and Particle Science, 1984, vol. 34, pp. 247-284.
Patent Assignee and Keyword Searches for Synchrocyclotron, Jan. 25, 2005, 78 pages.
Patent Assignee Search Paul Scherrer Institute, Library Services at Fish & Richardson P.C., Mar. 20, 2007, 40 pages.
Patent Prior Art Search for ‘Proton Therapy System’, Library Services at Fish & Richardson P.C., Mar. 20, 2007, 46 pages.
Pavlovic, Beam-optics study of the gantry beam delivery system for light-ion cancer therapy, Nuclear Instruments and Methods in Physics Research, Section A, Nov. 1997, 399(2):439-454(16).
Pedroni and Enge, Beam optics design of compact gantry for proton therapy Medical & Biological Engineering & Computing, May 1995, 33(3):271-277.
Pedroni et al., A Novel Gantry for Proton Therapy at the Paul Scherrer Institute, Cycloctrons and Their Applications 2001: Sixteenth International Conference. AIP Conference Proceedings, 2001, 600:13-17.
Pedroni et al., The 200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual design and practical realization, Medical Physics, Jan. 1995, 22(1 ):37-53.
Pedroni, Accelerators for Charged Particle Therapy: Performance Criteria from the User Point of View, Cyclotrons and their Applications, Proceedings of the 13th International Conference, Jul. 6-10, 1992, pp. 226-233.
Pedroni, E. and Jermann, M. “SGSMP: Bulletin Mar. 2002 Proscan Project, Progress Report on the PROSCAN Project of PSI,” [online] retrieved from www.sgsmp.ch/protA23.htm, (5 pages) Mar. 2002.
Pedroni, Latest Developments in Proton Therapy Proceedings of EPAC 2000, pp. 240-244, 2000.
Pedroni, Status of Proton Therapy: results and future trends, Paul Scherrer Institute, Division of Radiation Medicine, 1994, 5 pages.
Peggs et al., A Survey of Hadron Therapy Accelerator Technologies, Particle Accelerator Conference, Jun. 25-29, 2008, 7 pages.
Potts et al., MPWP6-Therapy III: Treatment Aids and Techniques Medical Physics, Sep./Oct. 1988, 15(5):798.
Pourrahimi et al., Powder Metallurgy Processed Nb3Sn(Ta) Wire for High Field NMR magnets, IEEE Transactions on Applied Superconductivity, Jun. 1995, 5(2):1603-1606.
Prieels et al., The IBA State-of-the-Art Proton Therapy System, Performances and Recent Results, Application of Accelerators in Research and industry—Sixteenth Int'l Conj, American Institute of Physics, Nov. 1-5, 2000, 576:857-860.
Proiect of PSI [online] retrieved from www.sgsmp.ch/protA23.htm, Mar. 2002, 5 pages.
Rabin et al., Compact Designs for Comprehensive Proton Beam Clinical Facilities, Nuclear Instruments & Methods in Physics Research, Apr. 1989, Section B, vol. 40-41, Part II, pp. 1335-1339.
Research & Development Magazine, Proton Therapy Center Nearing Completion, Aug. 1999, 41(9):2 pages (www.rdmag.com).
Resmini Design Characteristics of the K=800 Superconducting Cyclotron at M.S.U., Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, IEEE Transaction on Nuclear Science, vol. NS-26, No. 2, Apr. 1979, 8 pages.
RetroSearch Berkeley 88-Inch Cyclotron ‘RF’ or ‘Frequency Control’, Jan. 21, 2005, 36 pages.
RetroSearch Berkeley 88-Inch Cyclotron, Jan. 24, 2005, 170 pages.
RetroSearch Bernard Gottschalk, Cyclotron, Beams, Compensated Upstream Modulator, Compensated Scatter, Jan. 21, 2005, 20 pages.
RetroSearch Cyclotron with ‘RF’ or ‘Frequency Control’, Jan. 21, 2005, 49 pages.
RetroSearch Gottschalk, Bernard, Harvard Cyclotron Wheel, Jan. 21, 2005, 20 pages.
RetroSearch Loma Linda University Beam Compensation, Jan. 21, 2005, 60 pages.
RetroSearch Loma Linda University, Beam Compensation Foil Wedge, Jan. 21, 2005, 15 pages.
Revised Patent Keyword Search, Jan. 25, 2005, 86 pages.
Rifuggiato et, al., Status Report of the LNS Superconducting Cyclotron Nukleonika, 2003, 48:SI31-SI34, Supplement 2.
Rode, Tevatron Cryogenic System, Proceedings of the 12th International Conference on Highenergy Accelerators, Fermilab, Aug. 11-16, 1983, pp. 529-535.
Salzburger et al., Superconducting Synchrotron Magnets Supraleitende Synchrotronmagnete, NTiS, 155 pages (Oct. 1975).
Schillo et al,. Compact Superconducting 250 MeV Proton Cyclotron for the PSI Proscan Proton Therapy Project, Cyclotrons and Their Applications 2001, Sixteenth International Conference, 2001, pp. 37-39.
Schneider et al., Nevis Synchrocyclotron Conversion Program—RF System, IEEE Transactions on Nuclear Science USA, Jun. 1969, ns 16(3): 430-433.
Schneider et al., Superconducting Cyclotrons, IEEE Transactions on Magnetics, vol. MAG-11, No. 2, Mar. 1975, New York, pp. 443-446.
Schreuder et al., The Non-orthogonal Fixed Beam Arrangement for the Second Proton Therapy Facility at the National Accelerator Centre, Application of Accelerators in Research and Industry, American Institute of Physics, Proceedings of the Fifteenth International Conference, Nov. 1998, Part Two, pp. 963-966.
Schreuder, Recent Developments in Superconducting Cyclotrons, Proceedings of the 1995 Particle Accelerator Conference, May 1-5, 1995, vol. 1, pp. 317-321.
Schubert and Blosser, Conceptual Design of a High Field Ultra-Compact Cyclotron for Nuclear Physics Research, Proceedings of the 1997 Particle Accelerator Conference, May 12-16, 1997, vol. 1, 3 pp. 1060-1062.
Schubert et al., Progress toward an experiment to study the effect of RF grounding in an internal ion source on axial oscillations of the beam in a cyclotron, National Superconducting Cyclotron Laboratory, Michigan State University, Report MSUCL-760, CP600, Cyclotrons and their Applications 2011, Sixteenth International Conference, 2001, pp. 274-276.
Schubert, Extending the Feasibility Boundary of the Isochronous Cyclotron, Dissertation submitted to Michigan State University, 1997, Abstract http://adsabs.harvard.edu/abs/1998PhDt . . . 147S.
Shelaev et al., Design Features of a Model Superconducting Synchrotron of JINR, Proceedings of the 12th International Conference on High-energy Accelerators, Aug. 11-16, 1983, pp. 416-418.
Shintomi et. al, Technology and Materials for the Superconducting Super Collider (SSC) Project, The Iron and Steel Institute of Japan 00211575, 78(8): 1305-1313, 1992, [English Abstract included].
Siemens A.G., Erlangen (West Germany). Abteilung Technische Physik, Report No. BMFT-FB-T-75-25, Oct. 1975, p. 147, Journal Announcement: GRAI7619; STAR1415, Subm-Sponsored by Bundesmin. Fuer Forsch. U. Technol. In German; English Summary.
Sisterson, Clinical use of proton and ion beams from a world-wide perspective, Nuclear Instruments and Methods in Physics Research, Section B, 1989, 40-41:1350-1353.
Sisterson, World Wide Proton Therapy Experience in 1997, The American Institute of Physics, Applications of Accelerators in Research and Industry, Proceedings of the Fifteenth International Conference, Part Two, Nov. 1998, pp. 959-962.
Slater et al., Developing a Clinical Proton Accelerator Facility: Consortium-Assisted Technology Transfer, Conference Record of the 1991 IEEE Particle Accelerator Conference: Accelerator Science and Technology, vol. I, May 6-9, 1991, pp. 532-536.
Slater et al., Development of a Hospital-Based Proton Beam Treatment Center, International Journal of Radiation Oncology Biology Physics, Apr. 1988, 14(4):761-775.
Smith et al., The Northeast Proton Therapy Center at Massachusetts General Hospital Journal of Brachytherapy International, Jan. 1997, pp. 137-139.
Snyder and Marti, Central region design studies for a proposed 250 MeV proton cyclotron, Nuclear Instruments and Methods in Physics Research, Section A, 1995, vol. 355, pp. 618-623.
Soga, Progress of Particle Therapy in Japan, Application of Accelerators in Research and Industry, American Institute of Physics, Sixteenth International Conference, Nov. 2000, pp. 869-872.
Source Search “Cites of U.S. and Foreign Patents/Published applications in the name of Mitsubishi Denki Kabushiki Kaisha and Containing the Keywords (Proton and Synchrocyclotron),” Jan. 2005, 8 pages.
Spiller et al., The GSI Synchrotron Facility Proposal for Acceleration of High Intensity Ion and Proton Beams Proceedings of the 2003 Particle Accelerator Conference, May 12-16, 2003, vol. 1, pp. 589-591.
Stanford et al., Method of Temperature Control in Microwave Ferroelectric Measurements, Sperry Microwave Electronics Company, Clearwater, Florida, Sep. 19, 1960, 1 page.
Superconducting Cyclotron Contract awarded by Paul Scherrer Institute (PSI), Villigen, Switzerland, http://www.accel.de/News/superconducting_ cyclotron_ contract.htm, Jan. 2009, 1 page.
Tadashi et al., Large superconducting super collider (SSC) in the planning and materials technology,78(8):1305-1313, The Iron and Steel Institute of Japan 00211575, Aug. 1992.
Takada, Conceptual Design of a Proton Rotating Gantry for Cancer Therapy, Japanese Journal of Medical Physics, 1995, 15(4):270-284.
Takayama et al., Compact Cyclotron for Proton Therapy, Proceedings of the 81h Symposium on Accelerator Science and Technology, Japan, Nov. 25-27, 1991, pp. 380-382.
Teng, The Fermilab Tevatron, Coral Gables 1981, Proceedings, Gauge Theories, Massive Neutrinos, and Proton Decay, 1981, pp. 43-62.
The Davis 76-Inch Isochronous Cyclotron, Beam On: Crocker Nuclear Laboratory, University of California, 2009, 1 page.
The Journal of Practical Pharmacy,1995, 46(1):97-103 [Japanese].
The K100 Neutron-therapy Cyclotron, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL ), retrieved from: http://www.nscl.msu.edu/tech/accelerators/kl 00, Feb. 2005, 1 page.
The K250 Proton therapy Cyclotron, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/tech/accelerators/k.250.html, Feb. 2005, 2 pages.
The K250 Proton-therapy Cyclotron Photo Illustration, National Superconducting Cyclotron Laboratory at Michigan State University (NSCL), retrieved from: http://www.nscl.msu.edu/media/image/ experimental-equipment-technology /25 0 .html, Feb. 2005, 1 page.
Tilly, et al., Development and verification of the pulsed scanned proton beam at The Svedberg Laboratory in Uppsala, Physics in Medicine and Biology, Phys. Med. Biol. 52, pp. 2741-2454, 2007.
Tobias, C.A., et al., Pituitary Irradiation with High-Energy Proton Beams A Preliminary Report, Cancer Research, vol. 18, No. 2, pp. 121-134 (1958).
Tom, The Use of Compact Cyclotrons for Producing Fast Neutrons for Therapy in a Rotatable Isocentric Gantry, IEEE Transaction on Nuclear Science, Apr. 1979, 26(2):2294-2298.
Torikoshi, M. et al., Irradiation System for HIMAC, J. Radiat. Res, 48: Suppl. A15-A25 (2007).
Toyoda, Proton Therapy System, Sumitomo Heavy Industries, Ltd., 2000, 5 pages.
Trinks et. al., The Tritron: A Superconducting Separated-Orbit Cyclotron, Nuclear Instruments and Methods in Physics Research, Section A, 1986, vol. 244, pp. 273-282.
Tsuji, The Future and Progress of Proton Beam Radiotherapy, Journal of Japanese Society for Therapeutic Radiology and Oncology, 1994, 6(2):63-76.
U.S. Appl. No. 13/830,792, filed Mar. 14, 2013, including the USPTO electronic file for U.S. Appl. No. 13/830,792.
U.S. Appl. No. 13/949,459, filed Jul. 24, 2013, including the USPTO electronic file for U.S. Appl. No. 13/949,459.
U.S. Appl. No. 61/676,377, filed Jul. 27, 2012, including the USPTO electronic file for U.S. Appl. No. 61/676,377.
UC Davis School of Medicine, Unlikely Partners Tum Military Defense into Cancer Offense, Current Issue Summer 2008, Sacramento, California, pp. 1-2.
Umegaki et al., Development of an Advanced Proton Beam Therapy System for Cancer Treatment Hitachi Hyoron, 2003, 85(9):605-608 [Lang.: Japanese], English abstract, http://www.hitachi.com/ICSFiles/afieldfile/2004/06/01/r2003_ 04_I 04.pdf or http://www.hitachi.com/rev/archive/2003/2005649_12606.html (full text) [Hitachi, 52( 4), Dec. 2003].
Umezawa et al., Beam Commissioning of the new Proton Therapy System for University of Tsukuba, Proceedings of the 2001 Particle Accelerator Conference, vol. 1, Jun. 18-22, 2001, pp. 648-650.
Van Steenbergen, Superconducting Synchroton Development at BNL, Proceedings of the 8th International Conference on High-Energy Accelerators CERN 1971, 1971, pp. 196-198.
Van Steenbergen, The CMS, a Cold Magnet Synchrotron to Upgrade the Proton Energy Range of the BNL Facility, IEEE Transactions on Nuclear Science, Jun. 1971, 18(3):694-698.
Vandeplassche et al., 235 MeV Cyclotron for MGH's Northeast Proton Therapy Center (NPTC): Present Status, EPAC 96, Fifth European Partical Accelerator Conference, vol. 3, Jun. 10-14, 1996, pp. 2650-2652.
Vorobiev et al., Concepts of a Compact Achromatic Proton Gantry with a Wide Scanning Field, Nuclear Instruments and Methods in Physics Research, Section A., 1998, 406(2):307-310.
Vrenken et al., A Design of a Compact Gantry for Proton Therapy with 2D-Scanning, Nuclear Instruments and Methods in Physics Research, Section A, 1999, 426(2):618-624.
Wikipedia, Cyclotron http://en.wikipedia.org/wiki/Cyclotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Wikipedia, Synchrotron http://en.wikipedia.org/wiki/Synchrotron (originally visited Oct. 6, 2005, revisited Jan. 28, 2009), 7 pages.
Worldwide Patent Assignee Search, Jan. 24, 2005, 224 pages.
Worldwide Patent Keyword Search, Jan. 24, 2005, 94 pages.
Written Opinion for PCT/US2016/048037, 12 pages (dated Feb. 6, 2017).
Written Opinion for PCT/US2017/067677 (High-Speed Energy Switching, filed Dec. 20, 2017), issued by ISA/US, 7 pages (dated Apr. 30, 2018).
Wu, Conceptual Design and Orbit Dynamics in a 250 MeV Superconducting Synchrocyclotron, Ph.D. Dissertation, Michigan State University, Department of Physics and Astronomy, 1990, 172 pages.
York et al., Present Status and Future Possibilities at NSCL-MSU, EP AC 94, Fourth European Particle Accelerator Conference, pp. 554-556, Jun. 1994.
York et al., The NSCL Coupled Cyclotron Project—Overview and Status, Proceedings of the Fifteenth International Conference on Cyclotrons and their Applications, Jun. 1998, pp. 687-691.
Yudelev et al., Hospital Based Superconducting Cyclotron for Neutron Therapy: Medical Physics Perspective, Cyclotrons and their applications 2001, 16th International Conference. American Institute of Physics Conference Proceedings, vol. 600, May 13-17, 2001, pp. 40-43.
Zherbin et al., Proton Beam Therapy at the Leningrad Synchrocyclotron (Clinicomethodological Aspects and Therapeutic Results), Aug. 1987, 32(8):17-22, (German with English abstract on pp. 21-22).
Second Office Action (Chinese translation) for CN201480070002.6, 3 pages (dated Jan. 11, 2019).
Second Office Action (English translation) for CN201480070002.6, 4 pages (dated Jan. 11, 2019).
Final Office Action for U.S. Appl. No. 15/438,854, 30 pages (dated Nov. 28, 2018).
Final Office Action for U.S. Appl. No. 15/438,863, 30 pages (dated Nov. 28, 2018).
International Search Report for PCT/US2018/040211 (Configurable Collimator Controlled Using Linear Motors, filed Jun. 28, 2018), issued from ISA/EP, 6 pages (dated Nov. 16, 2018).
Office Action for U.S. Appl. No. 15/399,250, 8 pages (dated Jan. 24, 2019).
Written Opinion for PCT/US2018/040211 (Configurable Collimator Controlled Using Linear Motors, filed Jun. 28, 2018), issued from ISA/EP, 8 pages (dated Nov. 16, 2018).
Related Publications (1)
Number Date Country
20190001153 A1 Jan 2019 US
Provisional Applications (1)
Number Date Country
62527539 Jun 2017 US